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ABSTRACT
EXPRESSION AND IN VITRO PHOSPHORYLATION OF THE YEAST 
TRANSCRIPTIONAL ACTIVATOR ADR1
BY
Joel R. Cherry 
University of New Hampshire, September, 1988
The ADR1 protein activates transcription of the gene coding for the glucose 
repressible alcohol dehydrogenase II (ADH2) in Saccharomyces cerevisiae. 
Previous characterization of ADRjC mutations, which allow ADH2 to escape 
glucose repression, led to the hypothesis that ADR1 is inactivated post- 
translationally by a  cAMP-dependent phosphorylation mechanism. This 
hypothesis w as tested by investigating the in vitro phosphorylation of ADR1 
and ADR1C proteins in which ADR1C proteins were predicted to display a 
diminished level of phosphorylation. A fragment of the ADR1 gene coding for 
the N-terminal 658 amino acids was fused to the lacZ gene of E. coli to allow 
for identification and assay  of the ADR1 protein. The fused gene w as placed 
under the control of the E. coli lac promoter to ensure efficient production. 
Beta-galactosidase activities in plasmid-bearing E. coli indicated that ADR1/6- 
galactosidase fusion proteins were being expressed. SDS-polyacrylamide gel 
analysis of E. coli extracts revealed discrete plasmid-encoded fusion proteins.
Fusion proteins contained in crude E. coli extracts were phosphorylated in
vitro using purified catalytic subunit of mammalian cAMP-dependent protein 
kinase (cAPK). Peptide mapping results indicated that ADR1 was 
phosphorylated at two discrete sites in vitro. The primary phosphorylation site 
was identified as serine-230. A secondary site to the N-terminal side of serine- 
230 was also identified.
ADR1 DNA sequences were replaced in the expression plasmids with three 
sequences containing ADR1C mutations, each of which encodes a  single 
amino acid substitution within the phosphorylation sequence located between 
residues 227-231 (Arg-Arg-Ala-Ser-Phe). The in vitro phosphorylation of 
ADR1 and ADR1C containing fusion proteins were compared using both bovine 
cAPK and the yeast cAPK catalytic subunit encoded by the TPK1 gene.
Addition of purified yeast regulatory subunit completely blocked fusion protein 
phosphorylation by the yeast kinase in the absence of cAMP. The ADR1-2C and 
ADR1-50 mutations were found to diminish phosphorylation at serine-230. The 
ADR1-7C mutation, which substitutes a  leucine residue for serine-230, 
completely eliminated phosphorylation.
The results of this work support the hypothesis that the ADR1C proteins 
bypass glucose repression by avoiding phosphorylation and suggest that ADR1 
is regulated by a  cAMP-dependent phosphorylation. Possible mechanisms by 
which phosphorylation may regulate ADR1 activity are discussed.
xii
I. INTRODUCTION 
The ability of an organism to respond physiologically to changes in its 
environment is often dependent on the precise and timely control of gene 
expression. In the yeast Saccharomyces cerevisiae proteins of the respiratory 
chain, glyoxylate cycle and gluconeogenesis are repressed when the organism 
is grown in medium containing a fermentable carbon source such as glucose1'
11. When the fermentable carbon source is depleted, however, synthesis of 
proteins such a s  iso-1 -cytochrome c2, citrate synthase10, and alcohol 
dehydrogenase II11 is derepressed. Thus by altering its pattern of gene 
expression, yeast is able to metabolically adjust to changes in the availability of 
glucose. While the expression of many proteins is known to be modulated in 
response to changes in the extracellular environment, little is known about the 
molecular mechanisms responsible for these  changes. Because yeast are 
easily manipulated using both the techniques of classical genetics and 
molecular biology, it represents an ideal organism in which to study the control 
of eukaryotic gene expression. The present work investigates the mechanism 
by which the positive regulator ADR1 controls alcohol dehydrogenase II 
expression in yeast.
1
Alcohol dehydrogenase II (ADH II) is one of three active ADH isozymes 
found in S. cerevisiae. The metabolic function of two of the isozymes, ADH I 
and ADH II, was elucidated by the studies of Lutsdorf and Meg net11. The 
classical fermentative isozyme, ADH I, is a  cytoplasmic enzyme which catalyzes 
the NADH-linked reduction of acetaldehyde to ethanol13. ADH I plays a  vital 
role in the ceil during anaerobic growth by regenerating NAD-*- for use by the 
glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase. The ADH II 
isozyme is also localized to the cytoplasm, but appears to kinetically favor 
catalysis of the opposite reaction - the NAD+ linked oxidation of ethanol to 
acetaldehyde14. ADH II allows yeast to utilize ethanol as an energy and carbon 
source when glucose is unavailable. Cells unable to produce the fermentative 
isozyme due to mutation of the ADH1 gene* are viable under glucose growth 
conditions, but grow slowly due to the need to metabolize glucose aerobically. 
The other isozyme, ADH III, is expressed at very low levels14. Cells lacking this 
mitochondrially-associated isozyme are viable and appear not to be defective in 
any cellular functions, indicating that ADH III performs no essential metabolic 
function.
Transcription of the the classical fermentative isozyme, ADH I, is activated
"Throughout this work three letter gene designations will be underlined a s  is 
customary in yeast genetics. Three letter designations not underlined refer to 
the protein products i.e., ADB1 gene, ADR1 protein.
2
during growth in the presence of glucose and decreases approximately six-fold 
when cells are transferred to medium containing a  nonfermentable carbon 
source such a s  ethanol15. ADH II expression, on the other hand, is repressed at 
the level of transcription when cells are grown in the presence of glucose16. 
Magasanik, who demonstrated in bacteria that the repression of enzyme 
synthesis in response to glucose is mediated by some glucose catabolite rather 
than glucose itself, termed this catabolite repression17. ADH2 has come to be 
referred to a s  a  catabolite repressed gene, and the term may be apt since 
fermentable sugars other than glucose have been demonstrated to repress 
ADH II expression12.
When glucose is depleted from the growth medium or cells are grown in 
medium containing nonfermentable carbon sources, ADH II enzyme activity 
increases approximately 500-fold as ADH2 mRNA production is derepressed16. 
Derepression of ADH2 was first determined by Ciracy18*20 to be dependent 
upon the presence of the two trans-acting regulatory genes ADR1 and CCR1. 
Denis21 later demonstrated that there are two regulatory pathways controlling 
ADH2 expression: one consisting of the previously characterized positive 
activators ADR1 and CCR1. and the other consisting of a  positive effector, 






t +  /  V
CCR1 CRE1 CRE2
This model w as based on the epistatic relations of the various regulatory loci 
and does not necessarily imply that the proteins they encode interact directly. 
Because ADR1C mutations could be isolated which activated ADH2 expression 
in the absence of a  functional CCR1 gene, Denis concluded that ADR1 more 
directly affects ADH2 than does CCR1. ADR1 appears to be specific for the 
regulation of ADH2 expression since it does not affect the activities of several 
other enzymes subject to catabolite repression21,22. A recent report by Bemis 
and Dents23 concludes that ADR1 is required for growth in medium containing 
glycerol a s  the sole carbon source, although did not found affect the activity of 
som e enzymes involved in glycerol metabolism. ADR1 may therefore control a  
process required for the growth of cells in medium containing nonfermentable 
carbon sources other than glucose, but does not appear to be a  general 
activator of catabolite-repressed genes. In contrast, CCR1 and CCR4 are 
pleiotropic activators which have been shown to affect the expression of several 
glucose-repressed enzym es19,21. They may therefore encode proteins which
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play a  more universal role in transcription than does ADR1.
The ADR1 gene has been cloned24 and sequenced25 and is predicted to 
encode a  protein 1323 residues in length with a  calculated molecular weight of 
151 kilodaltons (KDa). ADR1 has been shown to be localized to the yeast 
nucleus via a  targeting sequence within its N-terminal 642 amino acids26, 
indicating that the protein may be intimately involved with the transcription of 
APH2.
ADR1 function has been elucidated largely through the characterization of 
recessive adr1 mutations and dominant ADR1C mutations. Strains carrying 
recessive adr1 mutations are unable to derepress transcription of ADH2 
normally, while strains carrying an ADR1° allele allow ADH2 transcription to 
occur in medium containing glucose.
The first of the adrl mutations to be characterized, adrl-1 . was found to 
contain an umber mutation at the eleventh codon position which blocks 
translation of the ADR1 protein (Lynne Bemis, personal communication).
Strains carrying this allele have virtually no ADH II enzyme activity18, indicating 
that the  ADR1 protein is essential to derepress transcription of ADH2 fTable 1a).
Strains carrying other ad d -ty p e  mutations fail to derepress ADH2 
transcription to varying extents (Figure 1a). These mutations were found to 
encode ADR1 proteins containing single amino acid substitutions within a  
region which sh a res  homology with the "zinc finger" DNA-binding sequence
Table 1.
a . ADH II Enzyme Activities







ADH II activities were taken from Cherry et al.27 with the exception of the 
values for the adr1-1 allele, which were taken from Bemis and Denis23. ADH II 
activities were determined a s  described16 following growth of cultures overnight 
at 30° C. Culture mediums contained YEP medium (2% yeast extract, 1% 
Bacto-peptone, 20 mg/L adenine and uracil) supplemented with either 8% 
glucose or 3% ethanol.








A D R 1-2°4C T to C 692 Phe to Ser 231
ADR1-5C G to A 683 Arg to Lys 228
ADR1-7® C to T 689 Ser to Leu 230
The identity of the ADR1-5C mutation is presented a s  reported by Denis and 
Gallo32. The identities of the ADR1-2C. ADR 1-4°. and ADR1-70 mutations are 
presented a s  reported by Cherry et al.27
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Figure 1
a. ADH II Activities of Strains Bearing adr1-5c -x Mutations




a d n -5 c-a 0 137
APF^1-5C 370 3400
ADH II activities were taken from Ref. 97 with permission from the author. 
ADH II activities were determined a s  described16 following growth of cultures 
overnight at 30° C. Culture mediums contained YEP medium (2% yeast extract, 
1% Bacto-peptone, 20 mg/L adenine and uracil) supplemented with either 8% 
glucose or 3% ethanol.
b. Location of adr1-x Amino Acid Substitutions in the Putative Zinc 
Finger
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Taken with permission from ref. 98. Drawn by D. Mullaney a s  adapted from 
Hartshorne et al. (ref. 25).
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motif first noted in the 5S rRNA transcriptional activator TFIIIA of Xenopus 
/aev/s26,27. These fingers, which are  repeated nine times in TFIIIA28, are 
repeated twice in AOR1 and occur between residues 98-126 and 127-155. 
Hartshome et al.25 have proposed, by analogy to TFIIIA, that these  regions of 
ADR1 form functional DNA-binding structures by coordinately binding Zn2+ ions 
as illustrated in Figure 1b.
This proposal is consistent with numerous studies which suggest that the 
ADR1 protein activates transcription of the ADH2 gene by binding directly to a  
region of DNA centered approximately 230 base  pairs (bp) upstream of the 
ADH2 transcription start site. This region, term ed an  upstream activating 
sequence or UAS, contains a 22 bp perfect inverted repeat. Deletion of the 
UAS from the ADH2 upstream region eliminates ADR1 -mediated
pg oqtranscription ' . Conversely, transcription of ADH2 was inhibited by 
placement of upstream sequences on multi-copy plasmids31. Inhibition w as 
relieved by placing a  copy of the ADR1 gene on th e  same plasmid31, 
presumably a s  a result of increased ADR1 expression. These results suggest 
that ADR1 interacts directly with the  ADH2 UAS an d  that this interaction is 
essential to  transcription.
The ADR1 protein may well require the zinc finger structures for binding to 
the ADH2 UAS. While metal binding has not yet been  demonstrated for the
8
intact ADR1 protein, a  synthetic peptide comprising amino acids of the C- 
terminal finger have been demonstrated to bind Zn2+ ions. Metal-dependent 
DNA binding was observed, but the peptide:Zn2+ complex failed to bind 
specifically to ADH2 upstream sequences (G. Parraga, personal 
communication). Therefore it appears that the fingers are necessary but not 
sufficient for sequence-specific binding of ADR1 to DNA. They may simply 
stabilize general ADR1-DNA interactions while the sequence specificity of 
DNA-binding is conferred by other sequences on the ADR1 protein.
Sequences just N-terminal to the fingers have been implicated in such a  role (T. 
Young, personal communication), but the mechanism of interaction has yet to 
be elucidated. Regardless of the role the finger regions play in ADR1 function, it 
is evident from the ADH II activities in strains carrying this second class of adr1 
mutations that these regions are essential to ADR1 activity.
Like the second class of adrl mutations, the ADR1C mutations were found to 
encode single amino acid substitutions within the ADR1 protein (Table 1b), but 
with a  different effect on ADH2 expression27'32 (Table 1a). These mutations 
allow ADH2 expression to partially overcome glucose repression, in some 
cases  increasing ADH II activity by 70-fold (Table 1a). Furthermore, since ADR1 
mRNA has been shown to be constitutively expressed and is independent of the 
ADR1 allele32, this data  implies that the ADR1 protein is present but inactive
under glucose repressed conditions. The ADR1C mutations must encode 
mutant proteins which can partially bypass the ADR1-inactivation mechanism.
Such a system of post-translational control of ADR1 is supported by studies 
which examined the effect of increased ADR1 gene dosage on ADH2 
expression33. Previous studies had shown that ADH II activity is directly related 
to the level of ADH2 mRNA transcribed16, therefore ADH II activities were used 
to provide a  measure of ADR1 activity. ADH II activities in glucose-grown cells 
were observed to increase linearly as the ADR1 gene dosage w as increased. A 
similar effect w as observed in strains with increased ADR1-50 dosages, 
indicating that the linear increase in ADH2 expression was the result of 
increased levels of ADR1 protein. In contrast, under derepressed growth 
conditions ADH It activities increased with increased ADR1 dosage until a  
maximum ADH II activity w as approached asymptotically. Strains carrying two 
to three copies of ADR1 had ADH II activities approximately one-half that of 
strains carrying a s  many a s  75 copies of ADR1. ADH2 expression in strains 
with high ADR1 dosage w as observed to increase when the dosage of ADH2 
w as increased, indicating that during derepression ADH2 expression was 
limited by the dosage of the ADH2 gene. These results imply that during 
glucose repression transcription of ADH2 is limited by the level of ADR1 protein, 
but that under derepressed conditions ADR1 protein can nearly activate ADH2
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transcription maximally. Increased levels of ADR1 protein may therefore 
override som e mechanism which normally inactivates ADR1 during glucose 
repression. Because strains with increased ADR1 dosage are phenotypically 
similar to strains with an ADR1C allele, the sam e ADR1 protein inactivation 
mechanism may be overridden or bypassed in both cases.
Characterization of the ADR1-50 mutation prompted Denis and Gallo32 to 
propose that the post-translational modification which renders ADR1 inactive 
during glucose growth is a  cAMP-dependent phosphorylation of the ADR1 
protein. The sequence Arg-Arg-Ala-Ser-Phe lying between residues 227-231 
of ADR1 is homologous to sequences recognized by type II cyclic AMP- 
dependent protein kinases (cAPK), Arg-Arg-X-Ser-Y, where Y tends to be a 
hydrophobic residue, X is not conserved, and the serine serves a s  the 
phosphoacceptor34,35. Four of the ADR1C constitutive mutations were cloned 
and sequenced, and all four were found to alter residues within this cAPK 
phosphorylation consensus site (Table 1b). ADR1-5C. the first of the constitutive 
mutations to be characterized, was found to encode a  protein in which the 
arginine residue at position 228 was replaced by a  lysine32. A synthetic peptide 
containing an ADR1-5c-like alteration in the phosphorylation consensus 
sequence w as determined by Kemp et al.35 to increase the Km of 
phosphorylation 16 fold relative to an ADR1-like sequence (see Figure 2).
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Similarly, the ADR 1-2° and ADR1-4C mutations, which were found to be 
identical (hence only ADR1-20 will be discussed), cause phenylalanine 231 to 
be replaced by a  serine27. Alteration of this amino acid, which is adjacent to the 
phosphoacceptor serine and normally occurs a s  a  hydrophobic residue, might 
also be expected to diminish phosphorylation by analogy to peptide studies 
carried out by Bramson et al.36 (Figure 2). The fourth constitutive mutation 
characterized, ADR1-7C. alters the putative phosphoacceptor serine to a  
leucine27. Such a  change would of course be expected to completely block 
phosphorylation at this site. Therefore all four of the constitutive mutants of 
ADR1 isolated thus far would be expected to diminish or eliminate 
phosphorylation of ADR1 at serine 230. Because the ADR1C proteins are able 
to cause  a  significant escape from glucose repression but only moderately 
elevate the level of ADH II expression in the absence of glucose, reversible 
phosphorylation of ADR1 was suggested by Denis and Gallo32 to be involved in 
the glucose repression of ADH2.
cAMP may therefore be one of the cellular signals which mediates glucose 
repression of ADH2. cAMP has been suggested to be involved in the 
inactivation of numerous enzym es necessary to nonfermentative growth in 
yeast including malate dehydrogenase37-39, fructose-1,6-bisphosphatase38*41, 
and phosphoenolpyruvate carboxykinase39. In the case  of fructose-1,6- 
bisphosphatase Tortora et al.45
12
Figure 2.
The Effect of Amino Acid Substitutions on the Kinetics of Synthetic  
Peptide Phosphorylation by B ovine cAPK
Kemp synthetic peptide ("Kemptide");
Leu Arg Arg A la S e r  Leu
ADR1 protein sequence (residues 226-232):












(ADR 1-5°) (ADR1-7C) WB^2PrAc)
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dem onstrated that cAMP-dependent phosphorylation of the yeast enzyme 
reduces its catalytic activity and is a  necessary step in its proteolytic 
degradation. cAMP-dependent phosphorylation is also known to be involved in 
the  regulation of trehalose and glycogen metabolism in yeast. The enzym es 
responsible for the synthesis and breakdown of the disaccharide trehalose, 
trehalose synthase and trehalase, are controlled coordinated by cAMP- 
dependent phosphorylation. Phosphorylation increases the enzymatic activity 
of trehalase43, while phosphorylation decreases the activity of the trehalose 
synthase complex42. A similar coordinate control system has also been 
determined to regulate enzym es involved in glycogen metabolism44. In all of 
these  cases the cAMP signal alters enzyme activity through direct 
phosphorylation of the protein. Interestingly, fructose-1,6-bisphosphatase 
contains significantly more phosphorylated serine residues when isolated from 
cells grown in medium containing glucose than in cells grown in medium 
containing a  nonfermentable carbon source41. This implies that cAMP- 
dependent phosphorylation is stimulated by the presence of glucose. Glucose 
h as  been observed to cause  a  dramatic, transient increase in the intracellular 
cAMP concentration in yeast46"48. In sum, the evidence suggests that in yeast 
glucose cau ses  increased cAMP-dependent phosphorylation of many proteins 
necessary for nonfermentative growth.
14
The enzym es presumably responsible for these phosphorylations, the yeast 
cAMP-dependent protein kinases (cAPK) are encoded by four genes, three of 
which encode catalytic subunits (TPK1. TPK2. and TPK3)49 while one codes for 
a  regulatory subunit (BCY1)50. The yeast cAPK, like its mammalian 
counterparts, exists as an inactive complex of regulatory (R) and a  catalytic (C) 
subunits in the absence of cAMP. When cAMP levels are increased the R 
subunits bind cAMP, causing dissociation of the complex and freeing active C 
subunits. In vitro studies indicate the yeast cAPK responds to cAMP in a  
manner analogous to the mammalian cAPK51, but the subunit stoichiometry in 
the active and inactive complexes has yet to be determined.
Of the three yeast catalytic subunits isolated thus far, only C 1 (encoded by 
TPK11 has been characterized biochemically52. In studies using synthetic 
peptides modeled after the mammalian cAPK consensus sequence 
("Kemptide"), C1 was shown to be capable of phosphoiylating this ADR1-like 
sequence with a  Km approximately 20-fold higher than the mammalian cAPK52. 
Yeast strains deficient in any two of the three TPK genes are viable, while 
strains lacking all three TPK genes grow very slowly49. This indicates that the C 
subunits which these  genes encode recognize sufficiently similar sequences 
that they can functionally substitute for one another in the cell. One of the C 
subunits may therefore be responsible for a  glucose-dependent
15
phosphorylation of ADR1.
The objectives of this work were to answer the following questions 
concerning the phosphorylation of ADR1:1) Is ADR1 phosphorylated by cAMP- 
dependent protein kinase in vitro? 2 ) if so, at what site(s) is it phosphorylated? 
and 3) do the characterized ADR1 constitutive mutations <ADR1-2C.ADR1-5C. 
and ADR1-7C) eliminate or diminish phosphorylation of ADR1 by cAPK?
To study the phosphorylation of the ADR1 protein it was necessary to create 
a  fusion protein which would allow both qualitative and quantitative detection of 
ADR1. To this end various fragments of ADR1 or ADR1C were fused to the lacZ 
gene of E. co/rand placed under the control of suitable yeast or E. coli 
promoters. Gene fusions on appropriate plasmid vectors were used to express 
ADR1/B-Galactosidase fusion protein in either organism, depending on the 
promoter contained in the plasmid constructs. The presence of such fusion 
proteins were then detected by published assay techniques in both cells 
extracts and whole cells, be they yeast or E  coli. In yeast, plasmids were 
expected to express fusion protein with two determinable functions- 6- 
galactosidase and ADR1. ADR1 activity would be  measured indirectly by 
assaying ADH II activity in strains in which the only functional ADR1 would be 
encoded by the plasmids.
Fusion proteins detectable in crude extracts w ere phosphorylated in vitro
16
using purified bovine or yeast cAPK in conjunction with radiolabeled ATP. 
Phosphorylated fusion proteins were examined by immunoprecipitation with 
anti-ADR1 or anti-0-galactosidase antibodies followed by fractionation on SDS- 
potyacrylamide gels. Determination of the site(s) of phosphorylation in ADR1 
was determined by peptide mapping of chymotryptic peptides derived from the 
phosphorylated fusion proteins.
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II. MATERIALS AND METHODS 
E. coli andY eastS tra ins. £  coli strains M182 (F', A(lac IOPZYAJX74, gal 
U, gal K, strAr) and RR1 (F‘, hsds20 (rg‘ , mg’), supE44, ara-14, proA2 , lacY1, 
galK2, rpsl_20 (strO, xyl-5, mtM.X*) were used. Yeast strain 500-16 (MATa 
adh1-11 adh3adr1-1 trp1 ural his41 contains a  nonsense mutation in ADR1 (L. 
Bemis, personal communication).
Growth Conditions. £. coli were grown overnight at 37° C in L broth (1% 
tryptone, 0.5% yeast extract, 0.5% NaCI, pH 7.5) containing ampicillin at a  
concentration of 50 pg/ml. Twenty milliliter cultures were used for protein 
analysis and 1.5 ml cultures were routinely used for plasmid DNA isolations. 3- 
galactosidase expression was screened for using MacConkey-lactose indicator 
plates containing ampicillin (50 g/L BBL MacConkey Agar (BBL Microbiology 
System s, Cockysville, MD), 25 mg/L ampilcillin). Colonies which appeared 
bright red after overnight growth indicated the presence of cells expressing 
levels of B-galactosidase activity in excess of 500 U/mg soluble protein.
Yeast were grown in 2 ml cultures overnight at 30° C with constant shaking . 
YEP medium (2% bactopeptone, 1% yeast extract, 20 mg/L adenine and uracil) 
containing 8% (w/v) glucose (YEP-GIc) or 3% ethanol (YEP-Et) was used for 
non-selective growth. W here indicated, the respiratory inhibitor antimycin A
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was added to a  concentration of 0.6pg/L. Trp~ medium contained 6.7 g/l yeast 
nitrogen base, 20 mg/mi adenine, uracil, and tyrosine, 5 g/L casamino acids, 
and 10 ml/L Trp dropout solution (0.5 g valine, 0.5 g threonine, 0.6 g 
phenylalanine, 0.2 g methionine, 0.4 g lysine, 0.6 g leucine, 0.6 g isoleucine,
0.2 g histidine, and 0.2 g arginine in 100 ml water) and w as supplemented with 
either 8% glucose (Trp-GIc) or 3% ethanol (Trp-EtOH). Selective plates used to 
screen for (3-galactosidase expression consisted of Trp-GIc medium buffered to 
pH 7 with 0.1 M potassium phosphate (5.32 g/L KH2PO4 ,10.63g/L  K2 HPO4) 
and supplemented with 25 g/L bactoagar. Just prior to use , 100 pi of X-Gal (5- 
bromo-4-ch!oro-3-indoyl-6-D-ga!actoside, 2% in dimethyl formamide) w as 
spread on the plate surface. Cells expressing 8-galactosidase activity in excess 
of 0.5 U/mg soluble protein appeared dark blue after two days growth at 30° C.
Plasmids. Plasmids used in this work are listed in Table 2. The 5' ADR1 
DNA sequences used in the construction of plasmids JC200Z and JC25 were 
derived from plasmid JS 1 19 constructed by Jeff Schuster a t Chiron Inc., 
Emeryville, CA. Plasmid JS 119 contains an Nco I site at the  start ATG of ADR1 
resulting from the ligation of a  synthetic 56 bp oligonucleotide to the 5' Hinc II 
site at bp +48 of ADR1. This oligonucleotide conservatively replaces the  5* end 
of ADR1 while providing a  new Nco I site at bp -1, and a  new  Bgl II site a t bp -7 
(Table 2b).
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Table 2a. P lasm ids Used in C onstructions
Plasmid Fragment of interest Source
pBR322 (E  coli vector) BRL
pUC19 (E  coli vector) BRL
YRp7-ADR1 -23A-6-5 ADR1 C. Denis27
YRp7-ADR1 (ABcl) ADR1 A. Rovelli*
JS119 ADR1 and G3PDH promoter J. Shuster*
YRp7-ADR1 -5C-23A ADR1-50 C. Denis24
YRp7-ADR1-2c ADR1-20 C. Denis27
YRp7-ADR1-7c ADR1-7C C. Denis27
PKK240-11 tag promoter M. Ptashne55
pRB45 lacZYA M. Rose54
pSKS105 lacZYA M. C asadaban
*These plasmids are described in Materials and Methods.
Table 2b. O ligonucleotide Seq u en ce Used In the Construction of
J S 1 1 9
Met Ala Asn Val Glu Lys Pro Asn Asp Cys Ser Gly Phe Pro Val 
AGA TCT ATT ACC ATG GCT AAC GTT GAA AAG CCA AAC GAT TGT TCT GGT TTT CCA GTT 
TCT AGA TAA TGG TAC CGA TTG CAA CTT TTC GGT TTG CTA ACA AGA CCA AAA GGT CAA
Bgl llA Nco lA Hinc llA
2 0
Plasmid YRp7-ADRl-3l 1 ABcl used in the construction of plasmid JC 1Z was 
constructed by Ann Rovelli in the Denis Laboratory by digestion of plasmid 
YRp7-ADR1-31124 with Bel I and subsequent religation. The resulting plasmid 
is identical to plasmid YRp7-ADR1-311 except that it lacks ADR1 sequences 
from bp -1600 to bp +440.
Plasmid Constructions. Restriction enzymes, bacterial alkaline 
phosphatase, and DNA ligase were purchased from New England Biolabs 
(Beverly, MA) or Bethesda Research Laboratories (Bethesda, MD). Plasmid 
purification from bacterial cells was performed essentially according to the 
method of Birnboim and Doly53 and is described in Appendix A. Restriction 
digestions were performed according to the manufacturers' specification using 
the LS, MS, HS or KS buffers described in Appendix B. DNA fragments were 
separated by agarose gel electrophoresis in TAE buffer and visualized under 
UV light after staining with ethidium bromide as described by Maniatis et al.57 
DNA ligations were performed a s  described in Appendix C. E. coli 
transformations were performed using competent RR1 or M182 cells either 
purchased from BRL (Bethesda, MD) or cells prepared by the CaCl2 procedure 
described by Maniatis et al.57 When necessary, transformants were screened 
by colony hybridization using an appropriate 32P-labeled ADR1 probe a s  has 
been described58.
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Preparation of Soluble Protein Extracts from Yeast Cells were recovered 
by centrifugation of overnight yeast cultures and cell pellets were washed once 
using 2 ml buffer A:200 ( 25 mM HEPES, pH 7 .5 ,5  mM MgCfc, 1 mM EDTA, 5 
mM B-mercaptoethanol, 1 mM phenylmethylsulfonyl chloride, 2 pM pepstatin,
0.6 pM leupeptin, 200 mM KCI). W ashed cells were resuspended in 200 pi 
buffer A:200 and glass beads (0.5 mm in diameter) were then added at a  ratio of 
approximately 1g per 100 pi cell suspension. Cells were then lysed at 4° C by 
vigorous mixing for approximately five minutes. Extracts were separated from 
the glass beads, spun in a  microcentrifuge for five minutes to remove insoluble 
debris, and stored on ice for immediate assay.
Preparation of Soluble Protein Extracts from E. coli. 20 ml cultures were
seeded with a  single red colony off of a  Mac-AMP plate and grown overnight at
37° C. The cells were collected by centrifugation at 3000 X g, transferred to 1.5
ml microcentrifuge tubes, and washed twice with 500 pi buffer A:200. The
washed cells were resuspended in 500 pi of buffer A:200 and lysed by
sonication at 0° C. Sonication was performed for 15-20 seconds at 80% power
using the 4 mm probe of a  Biosoniks Sonicator (VWR scientific, Brunswick, NJ).
Extracts appearing translucent after sonication indicated efficient lysis a s
judged by protein determination and B-galactosidase activity m easurem ents
(data not shown). Sonication of extracts for time periods in excess of 30
seconds resulted in loss of measurable enzyme activity. Extracts appearing
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opaque after after initial sonication were cooled on ice and sonicated for 5 to 10 
additional seconds. Translucent extracts were centrifuged at full speed  (13,000 
X g) in a  microcentrifuge for 15 minutes before removal of the supernatant 
fraction containing soluble proteins. Extracts were then placed on ice for 
immediate assay  or frozen in a  dry-ice/ethanol bath for long-term storage. 
Extracts could be stored for up to one month at -70° C with no appreciable loss 
in B-galactosidase enzyme activity.
Native Polyacrylamide Gel Electrophoresis. Native polyacrylamide gels
59were run a s  described .
Sodium Dodecvlsulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE1.
60Electrophoresis was performed according to the method of Laemmli with 
minor changes. Sam ples were mixed 1:4 with 5X SDS sam ple buffer (made by 
mixing a  warm solution containing 5 ml glycerol, 1 g SDS, and 2.5 ml 0.125 M 
Tris, pH 6.8 with 14.6 M B-mercaptoethanol in a  3:1 ratio just prior to use) and 
placed in a  boiling water bath for 3 minutes just before application to the 
polyacrylamide gel. Bromophenol blue w as added to the upper buffer chamber 
a s  a  tracker dye.
Gels were stained for protein using Kodak Kodavue (Rochester, NY), the 
Gelcode silver stain of Pierce Chemical Co., Rockford, IL., or using the silver 
stain protocol of Wray et al.61
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in Situ Staining of Protein Extracts with B-Galactosidase Activity. Native 
polyacrylamide gels were stained for B-galactosidase activity by washing for 15
^  go
minutes at 37^ C with Z buffer (0.1 M sodium phosphate pH 7.0 ,10 mM KCI,
imM MgS0 4 ) supplemented with 10 mM MnCl2 . Gels were then placed on a
glass plate with a  white background and coated with 200 pi Bluogal (BRL, 2%
solution in dimethylformamide). After incubation at room temperature for 15-20
minutes, proteins having B-galactosidase activity appeared a s  blue bands.
Extracts containing a s  low as 50 to 100 units of B-galactosidase activity
routinely yielded visible, albeit diffuse, bands.
B-galactosidase and ADR1 /B-galactosidase fusion proteins present in
extracts fractionated on SDS-PAGE were detected by activity staining .
60Electrophoresis was performed a s  described except that sam ples were not 
boiled after addition of sample buffer. After electrophoresis gels were first 
washed with water and  then w ashed twice for 30 minutes in 250 ml 10 mM Tris, 
pH 9, with water rinses between w ashes. After an overnight wash in Tris, gels 
were rinsed in water and washed for an additional 2 hours in Z buffer 
supplemented with 10 mM MnCl2 to activate the enzyme. Gels were then 
placed on a  white-backed glass plate and stained a s  was described above for 
native gels. Gels were covered with plastic wrap to prevent them from drying 
out and were allowed to develop for approximately two hours. Extracts with less
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than 300 units of B-galactosidase activity did not yield visible bands.
ADH Assays. Assays of ADH activity in yeast extracts were performed as 
previously described16 by mixing 0.89 ml ADH assay  buffer (18 mM sodium 
pyrophosphate pH 8.8 , 2.5 mM NAD+), 10 pi extract, and 100 pi 3 M ethanol in 
a  1 ml cuvette and measuring the change in absorbance at 340 nm. An 
extinction coefficient of 6.22 mM'1cm *1 was used for NADH. Activities are 
reported a s  millillnits ADH activity per mg protein where one Unit of ADH 
activity is defined as pmoles NAD+ reduced min"1 at 22° C. Protein assays
63were performed by the method of Lowry using bovine serum albumin a s  the 
standard.
B-Galactosidase Enzvme Assays. E. coli and yeast extracts were assayed
62essentially a s  described by Miller . Assay reaction mixes generally contained 
0.99 ml Z buffer, 10 pi soluble protein extract, and  0.2 ml o-nitrophenyl-B-D- 
galactoside (4 mg/ml in 0.1 M phosphate buffer, pH 7.0). Reactions were 
monitored by measuring the change in absorbance at 420 nm at 22° C.
Specific activity was defined a s  nmoles ONPG hydrolysed per minute per mg 
soluble protein using the formula:
(AOD42(}/min) (VT)
nmoles ONPG/min • mg =
((0.0045 cm -1 ml nmol*1 )(V/v)([protein])(1 cm)
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Where: AOD42o/min = change in absorbance at 420 nm/ minute 
VT = total assay volume (ml)
0.0045 cm-1 ml nmol' 1 is the extinction coefficient of ONPG62 
Va = volume of soluble protein extract (pi)
[protein] = protein concentration in mg/pl
63Protein assays were performed by the method of Lowry or using the BCA 
reagents of Pierce Chemical using bovine serum albumin a s  the standard.
Affinity Purification of B-Galactosidase Fusion Proteins. The synthesis 
and use of Sepharose-p-aminophenyl-1-thio-B-D-galactopyranoside in the 
purification of B-galactosidase fusion proteins was conducted according to the 
method of Ullmann . E. coli extracts were prepared a s  described above 
except that lysis was conducted in column application buffer (20 mM Tris, pH
7 .4 ,1 .6  M NaCI, 10 mM MgCl2).
Antibodies. Polyclonal rabbit anti-B-galactosidase antibodies were 
purchased from Cooper Biomedical, Inc. Malvern, PA. Anti-ADR1 polyclonal 
rabbit antibodies were kindly produced by Michael Morgan in the Denis 
laboratory by immunization of rabbits with a  synthetic peptide corresponding to 
amino acid residues 208-231 of ADR1 and will be described elsewhere.
Immunoorecioitations. ADR1/B-galactosidase fusion proteins were 
precipitated from E. coli extracts using anti-B-galactosidase antibodies under 
native conditions a s  previously described16. Precipitation of fusion proteins
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under denaturing conditions using anti-ADR1 antibodies was performed 
essentially a s  described65.
In Vitro PhosDhorvlationUsina_Bovine cAMP-Deoendent Protein 
Kinase. E, coli extracts were phosphorylated using the catalytic subunit of 
bovine cAMP-dependent protein kinase (Sigma P2645) in 10 mM Tris, pH 7.4,
4 mM MgCl2, 3 mM B-mercaptoethanol, 2 mM MnCl2 , 1 mM EDTA, 40 nM ATP,
2.6 X 10® cpm/pmol [y-32p] ATP. The amount of kinase used is given in 
picomolar units (pmol U) a s  defined by Sigma (1 pmol U is defined a s  the 
amount of enzyme required to transfer 1.0 pmol of phosphate from [y -32p] ATP 
to hydrolyzed and partially dephosphorylated casein per minute at pH 6.5 at 30° 
C.) In experiments where the kinase concentration w as varied the ATP 
concentration w as increased to 0.1 mM (2500 cpm/pmol [y -32p] ATP) such 
that it would not be limiting. Reactions were allowed to proceed for 10 minutes 
at 22° C. and w ere terminated by the addition of 5X SDS sample buffer 
followed immediately by immersion in a  boiling water bath for three minutes.
33Autoradiography of SDS polyacrylamide gels was a s  previously described .
In Vitro Phosphorylation Using Ye ast cAMP-Deoendent Protein Kinase 
Purified catalytic subunit of the yeast cAMP-dependent protein kinase 
encoded by the TPK1 gene w as the kind gift of Mark Zoller of Cold Spring 
Harbor Laboratory. Reactions were carried out using the protocol of
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66Roskowski . Reaction mixtures contained E. coli extracts, 50 mM MOPS (pH 
7.0), 10 mM MgCI2, 0.1 mM ATP (1000 cpm/pmol [y -32p] ATP), and 1.9 pg/ml 
purified C 1 kinase in 50 |il reaction volumes. Reactions were carried out and 
analyzed in a  m anner analogous to reactions using the bovine kinase 
described above.
Peptide Mapping of the ADR1 Phosphorylation Site Protein extracts 
containing the ADR1/ and ADR1c/6-galactosidase fusion proteins were 
phosphorylated in vitro and separated by SDS-polyacrylamide gel 
electrophoresis a s  described above. The phosphoproteins of interest were 
localized by autoradiography and excised from the dried gel. Chymotryptic 
digestion of the 177,175 KDa doublet and the 164 KDa single fusion protein 
w as performed essentially a s  described by Karess and Hanafuss67. Gel slices 
containing either the 177,175 KDa doublet or the 164 KDa fusion protein 
species were washed 4X for 15 minutes in 10% methanol at room temperature 
and lyophilized. Dried gel slices were treated with performic acid (performic 
acid was prepared by mixing one part 30% H20 2 with nine parts 90% formic 
acid followed by incubation on ice for one hour) for one hour on ice, washed 
twice with 1 ml water, and lyophilized. Dried performic acid-treated gel slices 
were then neutralized by washing 2X for five minutes with 1 ml 50 mM 
NH4HCO3 after which slices were washed with 1 ml water and lyophilized. The
28
resulting dried gel slices were incubated with 0.75 ml chymotrypsin (Sigma, 0.1 
mg/ml in 50 mM NH4HCO3) at 37° C for 15 hours. Peptides were eluted from 
the gel slices with 0.9 ml of water by shaking end-over-end for 12 hours at 4° C. 
The elution procedure w as repeated once and the combined supernatants were 
lyophilized. The resulting samples were then redissolved in 0.1 ml 50 mM 
NH4 HCO3 and redigested with 0.1 ml chymotrypsin for 6 hours. NH4HCO3 
was once again removed by lyophilization and the dried sam ples were 
resuspended in peptide-mapping sample buffer (1 M acetic acid, 0.05 M 
NH4OH, 8 M urea).
The chemically synthesized peptide Leu-Lys-Lys-Leu-Thr-Arg-Arg-Ala-Ser- 
Phe, representing ADR1 amino acid sequence 222-231, was used as a  
standard in the peptide mapping experiment. This peptide w as phosphorylated 
in vitro using bovine cAMP-dependent protein kinase in a  m anner analogous 
to the method described for labeling the E. coli extracts. The labeled peptide 
was purified on a  Sephadex G-15 column in 0.05 M NH4HCO3 . Fractions 
containing the phosphopeptide were identified by electrophoresis on a  50%
6flpolyacrylamide gel a s  described by W est and Bonner . Fractions containing 
phosphorylated peptide were lyophilized and an aliquot was removed for 
treatm ent with chymotrypsin. Chymotrypsin digestion of the synthetic peptide 
was performed in parallel with digestions of proteins contained in the gel slices
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a s  described above. A phosphorylation mix lacking a  peptide or ADR1/B- 
galactosidase fusion protein substrate was also digested in parallel a s a  
control.
Final analysis of the phosphorylated peptides w as conducted using the 50%
pH 3 polyacrylamide gel electrophoresis system described by West and 




Expression of ADR1/B-Galactosidase fusion protein in Yeast. Expression of 
ADR1 in S. cerevisiae was accomplished using plasmids in which fragments of 
the ADR1 gene were ligated to the lacZ gene which codes for B-galactosidase. 
The ADRl/lacZ fragments were placed under the control of the glyceraldehyde-
693-phosphate dehydrogenase (G3PDH) promoter and inserted into the yeast 
plasmid vector YRp7. The G3PDH promoter was chosen for its efficiency in 
promoting transcription; G3PDH mRNA normally accounts for 2-5% of the total 
yeast poly A mRNA70. These expression plasmids were therefore expected to 
produce high levels of ADR 1/B-galactosidase fusion protein. Fusion proteins 
were predicted to be bifunctional, having both ADR1 acivity and B- 
galactosidase activity. B-Galactosidase activities were to be a  m easure of the 
amount of ADR1 /B-galactosidase fusion protein, while ADH II enzyme activity 
was predicted to provide an accurate m easure of the amount of functional ADR1 
protein present. Denis has shown that under glucose growth conditions the 
level of ADH II activity is directly proportional to the ADR1 or ADR1-5C gene 
dosage33. Due to possible problems with degradation or stability of the ADR1 
portion of the fusion proteins, 8-galactosidase activities may be a  less reliable 
m easure of the amount of functional ADR1 produced than is ADH II enzyme 
activity.
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Two yeast ADR 1 /G-galactosidase expression plasmids were used. The first 
plasmid, JC1Z, contains DNA sequences encoding the N-terminal 304 amino 
acids of ADR1 fused in frame to eigth codon of lacZ (Figure 3). The second 
yeast expression plasmid, JC25, contains sequences coding for a  larger fusion 
protein containing 658 ADR1 amino acids fused to the sixth codon of lacZ 
(Figure 4).
These plasmids were transformed into yeast strain 500-16 fad rl-1 . tro ll and 
the expression of plasmid-encoded fusion proteins w as tested by growing cells 
on complete medium lacking tryptophan which had been supplemented with 
the chromogenic 6-galactosidase substrate X-Gal. The formation of small 
colonies that were deep blue in color.confirmed that fusion proteins with 13- 
galactosidase activity were being expressed. Plasmid-bearing cells grew very 
slowly relative to plasmid-free controls. In addition, expression plasmids were 
poorly maintained, even under selective growth conditions. This suggests that 
ADR1 / 6-galactosidase overexpression may be toxic to the cell.
The level of ADR 1/ 6-galactosidase fusion protein expression w as measured 
by assaying transformants for 6-galactosidase and ADH II under various 
selective growth conditions (Table 3). Cells containing plasmid were selected 
for by growth in rich medium lacking tryptophan, by growth in the presence of 
the respiratory inhibitor antimycin A, or by using cells which had spontaneously
Figure 3
Construction of Yeast AD RI/B-G alactosidase E xpression  Plasm id
JC1Z
ADR1 sequences used in the construction of plasmid JC1Z were derived 
from plasmids YRp7-ADR1-311ABcl and JS 1 19, both of which are described in 
Materials and Methods. The Bam Hl-Bcl I fragment of JS 1 19 containing the 
G3PDH promoter and the first 440 nucleotides of the ADR1 coding sequence 
was ligated into the unique Bel I site of YRp7-ADR1-311ABcl to create plasmid 
JC 1. JC1 was cut a t the unique Bam HI site at +907 and ligated into plasmid 
pSKS10556 at the Bam HI site in the polylinker. The resulting plasmid, JC1Z, 
encodes a  fusion protein containing the 304 N-terminal ADR1 residues fused to 
the seventh amino acid of B-galactosidase. Expression of the ADR1/iacZ gene 
fusion is controlled by the G3PDH promoter and the plasmid is selectable on 
medium lacking tryptophan when present in a  yeast strain containing the trp1 
allele.
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Construction o f Yeast ADR1/Q-Galactosidase E xpression Plasm id
JC 25
Plasmid JC25 w as constructed by inserting the 8.6 kb Bam Hl-Sal I fragment 
from JC100Z (described in Figure 5) into yeast vector YRp7. The final JC25 
construct contains codons for amino acids 1 to 658 of ADR1 fused in frame to 
the sixth codon of the lacZ' gene.
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Figure 4: Plasmid JC25 Construction
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Table 3 . ADR1/B-Galactosldase Fusion Protein E xpression In Yeast
a ' nmoles ONPG hydrolysed per minute per mg soluble protein. All assay 
values are the average of a  minimum of three separate determinations.
k  pmoles NADH oxidized per minute per mg soluble protein.
c“ Yeast strain 500-16 fadrl -1) containing no plasmid a s  determined by Bemis 
and Denis23. All strains assayed except ADR1-304 are isogenic to strain 
500-16.
■ YEP medium contains 2% w/v bactopeptone, 1% w/v yeast extract, 20 mg/L 
adenine and uracil and was supplemented with either 8% glucose (YEP- 
Glc) or 3% ethanol (YEP-EtOH).
e ‘ Trp- medium contained 6.7 g/l yeast nitrogen base, 20 mg/ml adenine, 
uracil, and tyrosine, 5 g/L casamino acids, and 10 ml/L Trp dropout solution 
(0.5 g valine, 0.5 g threonine, 0.6 g phenylalanine, 0.2 g methionine, 0.4 g 
lysine, 0.6 g leucine, 0.6 g isoleucine, 0.2 g histidine, and 0.2 g arginine in 
100 ml water) and was supplemented with either 8% glucose (Trp-GIc) or 
3% ethanol (Trp-EtOH).
f' YEP medium containing 8% glucose and 0.6 pg/ml antimycin A.
y‘ Assay values a s  determined by Bemis and Denis for strain 500-16 
carrying a  plasmid which encodes the N-terminal 642 amino acids of ADR1 
under the control of the ADR1 promoter. Values are  shown for strains 
carrying either a  single integrated plasmid copy or free plasmid a s  indicated.
h' Assay values a s  determined by Denis and Young24 for strain 500-16 
carrying a  plasmid which encodes the N-terminal 304 amino acids of ADR1 
under the control of the ADR1 promoter. Values are shown for strains 
carrying either a  single integrated plasmid copy or free plasmid a s  indicated.
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become respiration deficient due to irreversible mitochondrial petite mutation. 
Petite cells and cells grown in the presence of antimycin A must ferment 
glucose to obtain energy. ADH II is required for fermentation in these cells 
since the yeast strain transformed lacks the fermentative isozyme ADH I. 
Because ADR1 is required for ADH II production, petite cells or cells grown in 
the presence of antimycin A must maintain ADR 1-expressing plasmid to survive. 
Respiration deficient cells bearing plasmid JC25, whether petite or grown in the 
presence of antimycin A, had ADH II and 13-galactosidase activities 9-fold 
greater than found in cells grown in tryptophan-deficient medium. Plasmid 
JC1Z-induced ADH II and 13-galactosidase activities were 2-fold higher in cells 
grown in the presence of antimycin A than found in cells grown in tryptophan- 
deficient medium. (3-galactosidase and ADH II activities therefore indicate that 
respiration deficient cells selected more strongly for plasmids JC25 and JC 1Z 
than did cells grown on medium lacking tryptophan.
It should also be noted in Table 3 that under glucose growth conditions there 
w as a  direct correlation between 13-galactosidase activity and ADH II activity. In 
strains carrying JC25, the ratio of ADH II activity to 13-galactosidase activity 
(mll/ll) is approximately 120 mll/U, while in JC1Z-strainsthe ratio is 14 mU/U. 
These data indicate that under glucose growth conditions 13-galactosidase 
activity provides a  good m easure of the amount of functional ADR 1/0-
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galactosidase activity. Furthermore, it also indicates that the smaller JC 1Z- 
encoded fusion protein has approximately one-ninth the transcriptional 
activation activity (or ADR1 activity) of the JC25-encoded fusion protein, 
assuming that the respective fusion proteins have similar 13-galactosidase 
activities and are not differentially degraded by the cell. The efficiency of fusion 
protein expression was therefore measured by comparison of the ADH II 
activities of cells bearing plasmids JC25 or JC 1Z to cells bearing plasmids with 
similar-sized ADR1 truncations under the control of the ADR1 promoter.
The ADH II activity of strain 500-16 carrying plasmid JC25 can be compared 
to the ADH II activity of the sam e strain carrying ADR1-642, a  plasmid 
constructed by Bemis and Denis23, when plasmids are maintained by growth in 
the presence of the respiratory inhibitor antimycin A (At). Plasmid ADR1-642 
contains a  truncated ADR1 gene encoding the N-terminal 642 amino acids of 
ADR1 under the control of the ADR1 promoter. JC25 was designed to produce 
an  ADR1/8-galactosidase fusion protein containing 659 N-terminal residues of 
ADR1. Comparison of ADH II activities in cells rendered respiration deficient 
indicates that JC 25 produces about 3-fold more ADR1 activity than does the 
ADR1-642 plasmid. Similarly,the ADH II activities of cells carrying plasmid 
ADR1-30424 can be compared to cells carrying JC1Z since both plasmids 
contain ADR1 sequences coding for the N-terminal 304 amino acids of ADR1.
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500-16/JC1Z ADH II activities were found to be 0.7-fold that of the ADH II activity 
of 500-16/ADR1 -304 when cells are  grown in the presence of antimycin A. 
Therefore under conditions which maximize expression, the JC1Z plasmid 
expresses slightly less active ADR1 protein than comparable plasmids with 
ADR1 promoters, while the JC25 plasmid expresses more. This indicated that 
the expression or stability of the JC 1Z protein, unlike its JC25 counterpart, is 
adversely affected by the fusion with 13-galactosidase under glucose growth 
conditions.
Under ethanol growth conditions the ADH II activity in strains carrying 
plasmid JC25 rose 90 milliunits per unit of 13-galactosidase, while the ADH II 
activity in strains carrying plasmid JC1Z rose 280 milliunits per unit of 8- 
galactosidase. Thus the JC1Z was a  more efficient activator of ADH2 
transcription under ethanol growth conditions than under glucose growth 
conditions (mU ADH ll/U 8-gal = 13 for glucose, 280 for ethanol). JC25- 
encoded fusion protein, on the other hand, w as slightly less efficient on ethanol 
than on glucose (mU ADH ll/U 8-gal = 120 for glucose, 90 for ethanol). 
Furthermore, derepressed ADH II activites in strains carrying plasmids were 
significantly less than strains expected to express similar sized ADR1 proteins 
from truncated ADR1 genes integrated in the genome (compare JC25 and 
JC1Z activities to ADR1-642 and ADR1-304 integrant activities under ethanol 
growth conditions).
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Despite the fact that the ADH II activities of strains bearing plasmid JC25 or 
JC1Z grown under derepressing conditions were much lower than expected, 
ADH2 was still significantly derepressed. In the case  of JC1Z, 13-galactosidase 
activities indicated that approximately three-fifths a s  much fusion protein was 
m ade under ethanol growth conditions as under glucose growth conditions, yet 
ADH II activity was derepressed 13-fold. JC25 gave about a  3-fold 
derepression of ADH2 and B-galactosidase activities indicated that there was 
2.9-fold more fusion protein present under ethanol growth conditions. This 
discrepancy in correlating (3-galactosidase activities with ADH II derepression is 
thought to be an artifact which arose due to the extremely poor growth of cells 
bearing plasmid JC25 when grown in ethanol containing medium.
Attempts to detect plasmid-encoded ADR1/13-galactosidase fusion protein in 
yeast extracts were unsuccessful (data not shown). Silver staining of SDS- 
polyacrylamide gel lanes containing anti-B-galactosidase antibody precipitates 
and yeast extracts failed to detect the presence of any proteins unique to 
plasmid-bearing cells. Assuming that ADR1/0-galactosidase fusion proteins 
have specific activities comparable to purified 13-galactosidase (purified 0- 
galactosidase has a  specific activity of 3 X 105 U/mg62), fusion proteins were 
estimated to account for approximately 0.004% of the soluble protein in 
respiratory deficient strains bearing plasmid JC25. This estimate may be low as
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numerous 13-galactosidase fusion proteins have been shown to have specific 
activities significantly lower than wild-type 13-galactosidase .
Expression of ADR1/ and ADRjC/B-Galactosidase Fusion Proteins in E. coli. 
Plasmids containing portions of the ADR1 coding sequence were ligated in 
frame to the lacZ* gene and placed under the control of the lac  promoter. The 
lac promoter was constructed by de Boer and coworkers71 by fusion of the E. 
coli lcc "-35" (T-T-G-A-C-A) and lac UV-5 Pribnow box (T-A-T-A-A-T) promoter 
regions. Transcription from this extremely efficient synthetic hybrid promoter is 
repressed by the lac repressor and can be derepressed by the addition of the 
fortuitous inducer isopropyl thiogalactoside (IPTG).
Two constructs, JC200Z and p6a45 (Figures 5 and 6), were used to 
produce ADR1/B-galactosidase fusion proteins in E. coli. Plasmid JC200Z 
w as predicted to produce a  fusion protein of 191 KDa containing the N-terminal 
659 amino acids of ADR1 fused to the eighth amino acid of B-galactosidase. 
Plasmid p6a45 w as designed to produce a  slightly smaller fusion protein of 187 
KDa and containing ADR1-5C protein sequences from amino acid 17 to 642.
E. coli strains M182 (lac~) and RR1 (lac+) were transformed with plasmid 
6a45 or JC200Z. Cells bearing either expression plasmid appeared red and 
were distinguishable from yellow control strains when examined 12 to 20 hours 
after plating on MacConkey-lactose indicator plates containing ampicillin.
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Figure 5
Construction of E. coll ADR1/ and ADR1c /B -G alactosidase  
Expression P lasm ids in the JC200Z Series
ADR1 sequence derived from plasmid JS 119 w as used in the construction 
of JC200Z. A 2.4 kb BamHI- Hindll fragment of JS 1 19 encompassing ADR1 
sequences from +1 to +1971 was inserted into the polytinker of E. coli vector 
pUC19 to create plasmid JC100. A 1.9 kb Hinc ll-Hind 111 fragment containing 
ADR1 coding sequences from +48 to +1971 was removed from JC100 and 
replaced with a 622 bp Hinc ll-Hind III fragment from pBR322 to create plasmid 
JCO. This "stuffer" DNA was inserted to eliminate contamination of ligation 
reactions with ADR1 sequences during subsequent introduction of ADR1C 
sequences. JC102, JC105, and JC107 were then created by replacing the 
stuffer DNA in JCO with 1.9 kb Hinc ll-Hind III fragments from plasmids YRp7- 
ADR1 -2°, YRp7-ADR1 -5C, and YRp7-ADR1 -7© respectively. A 2.4 kb BamHI- 
Hindll fragment of JC100, JC102, JC105, or JC107 encompassing ADR1 or 
ADR1C sequences from +1 to +1971 w as inserted into the polylinker of 
pSKSIOS56 to create in-frame ADR 1-lac Z' fusions in JC100Z, JC102Z, JC105Z, 
or JC107Z. An 8 kb Nco l-Nco I fragment from the start of ADR1 to the end of 
the lac operon was isolated from these  plasmids and inserted into pKK240- 
1155 at a  unique Nco I site downstream from the tac  promoter. The final JC200Z 
series constructs contain codons for amino acids 1 to 658 of ADR1 or ADR1C 
fused in frame to the sixth codon of the lac Z  gene.
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Figure 5:JC200Z Series Plasmid Constructions
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Construction of E. coll ADR1-5c /8-G alactosIdase E xpression
Plasm id 6a45
For plasmid p6a45 the Hinc ll-Bam HI 3.2 kb fragment of plasmid YRp7- 
ADR1-5C-23A16 w as ligated into plasmid pKK240-1155 at the Hind III site after 
both fragments had been rendered blunt-ended using the Kienow fragment of 
E. coli polymerase I. The unique Hind III site in plasmid pKK240-11 is situated 
such that a  tag promoter, an ATG start codon, and two additional codons were 
fused in frame to the 17th codon of ADR.1-50 upon ligation. This plasmid, 
designated p6a, w as then digested with Bgl II and Bam HI and the resulting 2.1 
kb fragment containing the tac promoter and a  portion of the ADR1-5C gene 
was ligated into the Bam HI site of lacZ vector PRB4554. The final construct, 
p6a45, contains codons for amino acids 17-642 of ADR1-5C fused in-frame to 
the lac Z  gene at codon eight. The nucleotide sequence of the pKK240-11/ 
ADR 1-5° junction is shown the lower right corner.
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Figure 6: Construction of nlaemld 6a45
Amp^
YRp7-ADR1 -5^23A 
3.2 Kb Hinc ll-BamHI fragment 





2.3 kb Bam Hl-Bgl II fragment inserted into a  







ATG GAA GOT GAC TTG 





Some cells were observed to lose the ability to express B-galactosidase after 
repeated plating a s  indicated by their inability to produce the characteristic red 
bile salts. This result was interpreted to be indicative of plasmid loss or 
mutation; cells which had lost their ability to yield red colonies were discarded.
Extracts of cells containing plasmid p6a45 and JC200Z were prepared and 
assayed for B-galactosidase activity a s  described in Materials and Methods. E. 
coli plasmids were found to express significantly more B-galactosidase activity 
than comparable yeast plasmids (Table 4). JC200Z, which is predicted to 
produce a  fusion protein identical to that produced by the yeast vector JC25, 
expressed approximately 300 fold more B-galactosidase activity than its yeast 
counterpart. E. coli fusion proteins were estimated to account for 1 -2% of the 
total soluble protein in the E. coli cell extracts. Fusion protein production was 
found to be relatively insensitive to the strain differences.
Detection of Fusion Proteins Produced bv Plasmids JC200Z and 6a45. 
Protein extracts from plasmid-bearing cells were fractionated on SDS- 
polyacrylamide gels and stained for protein (Figure 7a). Protein extracts 
derived from E  coli carrying plasmid JC200Z contained five discrete fusion 
proteins which were unique to plasmid-bearing cells. These proteins had 
relative molecular weights of 182 ,177 ,175 ,164 , and 122 KDa. The size of the 
largest fusion protein detected, 182 KDa, is in approximate agreem ent with the
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Table 4
B-Galactosldase Activities of ADR1 /(VGalactosidase Fusion  
Proteins Expressed in E. coll








a  nmoles ONPG hydrolysed per minute per mg soluble protein.
62Assays were performed essentially a s  described by Miller . All assay 
values are the average of a  minimum of three separate determinations. Cells to 
be assayed were grown at 37° C overnight in L-broth supplemented with 50 
pg/ml ampiciilin and were lysed at 0° C by sonication in buffer A:200 ( 25 mM 
HEPES, pH 7 .5 ,5  mM MgCl2 , 1 mM EDTA, 5 mM 6-mercaptoethanol, 1 mM 
phenylmethylsulfonyl chloride, 2 |iM pepstatin, 0.6 pM leupeptin, 200 mM KCI).
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predicted size of 190 KDa for the full-length JC200Z fusion protein. The 182, 
177,175, and 164 KDa fusions appear to be present at approximately equal 
concentrations, while the 122 KDa species is significantly more abundant than 
the other fusions. Densitometric quantitation of the 122 KDa species relative to 
the higher molecular weight fusions was impeded by negative staining of this 
protein on silver-stained gels.
The four truncated fusion proteins smaller than 182 KDa could have been 
the result of transcription or translation initiation from within the ADR1 coding 
sequence or of specific proteolysis of the full-length fusion protein. Searches 
for prokaryotic promoter elements72 or ribosome binding sites (Shine-Delgamo 
sequences)73 within ADR1 revealed no such homologies. If the truncations 
were the result of specific proteolysis, the degradation m ust have occurred 
within the cell prior to lysis since cells lysed by boiling in SDS-sample buffer 
produced the sam e gel pattern a s  cells lysed by sonication in the absence  of 
protease inhibitors (data not shown).
Plasmid p6a45 w as observed to produce a  pattern of five discrete fusion 
protein products similar to that obtained with JC200Z (Figure 7a). The largest of 
these, presumably the full-length fusion protein, had a  slightly greater mobility 
than the full-length JC200Z fusion protein. This was consistent with the 
predicted difference in molecular weight between the two proteins, a s  JC200Z
Figure 7. Detection of ADR1/B-Galactosidase Fusion Proteins in E. coll
a .  Identification of ADR1/B-galactosidase fusion proteins. Silver- 
stained SDS-polyacry!amide gel of extracts from E  coli containing either the 
control plasmid pKK240-11, plasmid JC200Z, or plasmid p6a45. Numbers at 
the left of the gel refer to molecular weights of marker proteins in KDa, 
arrowheads indicate plasmid-encoded fusion proteins with calculated 
molecular weights of 182,177, 175,164, and 122 KDa for JC200Z and 180,
175 (two comigrating proteins), 162, and 120 KDa for p6a45. The gel w as 
stained with Gelcode silver stain (Pierce Chemical Co., Rockford, IL)
b. In  vitro phosphorylation of ADR1/B-galactosidase fusion  
proteins. Autoradiogram of the gel pictured in a. showing fusion proteins 
phosphorylated by bovine cAMP-dependent protein kinase in vitro. Reactions 
were performed a s  described in Materials and Methods with bovine cAPK at a  
concentration of 1 pmol U/pl.
d. Precipitation o f phosphorylated fusion  proteins using anti-ADR1 
antibodies. Antibodies raised against a  synthetic peptide containing ADR1 
amino acids 208-231 were used to precipitate ADR1-containing fusion proteins 
from denatured extracts of E. coli strain M182 carrying the plasmid indicated at 
the top of each lane.
d. Precipitation of phosphorylated fusion  proteins using anti-B- 
galactosid ase  antibodies. Autoradiogram of whole extracts and anti-8- 
galactosidase antibody precipitates of extracts of E  coli strain RR1 carrying 
no plasmid (controls) or plasmid p6a45.
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was predicted to produce a  190 KDa protein while p6a45 was predicted to 
produce a  186 KDa protein. With the possible exception of the 122 KDa 
species, the truncated products of p6a45 also appear to be slightly reduced in 
size when compared to their JC200Z counterparts.
The fusion proteins in extracts of E.coli strain M182 (lac) carrying plasmid 
p6a45 were partially purified on a sepharose-p-aminophenyl-1-thio-8-D- 
galactopyranoside B-galactosidase affinity column. Peak fractions were 
inspected for fusion proteins using SDS-PAGE (Figure 8). The elution fraction 
having the highest B-galactosidase activity also contained numerous proteins 
which were presumably bound non-specifically to the affinity resin despite the 
use of the high-volume, high-stringency washing procedure of Ullmann (100 
column volumes with 1.6 M NaCi in phosphate buffer). Of the identified fusion 
proteins, only the 122 KDa fusion protein species appeared to be significantly 
enriched (Figure 8 ; compare p6a45 lane to ACF lane). This fusion protein, 
which is in the greatest abundance of all the fusion proteins in crude extracts, 
must therefore have B-galactosidase activity. While the other fusion species 
may also have activity, their affinity to the column may be detrimentally affected 
by the presence of the N-terminal ADR1 sequences. It is unlikely that the 
abundant 122 KDa species sterically excluded the other fusion proteins from 
binding to the resin a s  the column was significantly under-loaded (see Figure 8
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Figure 8
SDS-PAGE of 8-G alactosidase Affinity Column Peak Fraction
P rotein s
Silver stained SDS-polyacrylamide gel analysis of affinity purified fusion 
proteins encoded by plasmid p6a45 in E. coli strain M182 (lane designated 
ACF for Affinity Column Eraction). Reference lanes contain extracts of strain 
M182 bearing no plasmid or plasmid p6a45, as indicated. Numbers to the left 
of the gel indicate the mobilities of marker proteins with molecular weights in 
KDa. The arrowhead on the right indicates the 122 KDa fusion protein, a s 
discussed in the text.
Approximately 2 mg of soluble protein containing 8800 units of 8- 
galactosidase activity was applied to a  1 ml 8-galactosidase affinity column 
(capacity estimated to be 84,000 units) prepared according to Ullmann64. The 
column was washed with 100 column volumes of high-salt wash buffer to 
remove non-specifically bound proteins. Proteins having 8-galactosidase 
activity were eluted from the column with 100 mM sodium borate, pH 10 ,10  mM 
8-mercaptoethanol. 0.5 ml fractions were collected and assayed essentially as
eo
described . The second and third fractions were found to contain -80%  of the 
activity loaded and represented an approximately 7-fold purification. Peak 
fractions were pooled and concentrated and an aliquot containing 15 pg of 










Extracts of E. coli bearing p6a45 were also analysed using native PAGE 
followed by in situ activity staining for B-galactosidase (Figure 9). Only a  single 
diffuse band of B-galactosidase activity was observed. This band was excised 
and re-fractionated using SOS-PAGE. The only active band observed was 
identified a s  the 122 KDa fusion protein (Figure 9). Therefore, although all the 
fusion proteins could have B-galactosidase activity, B-galactosidase activity was 
only detected in the 122 KDa species.
In Vitro Phosphorylation of ADR1/BGalactosidase  Fusions Using Bovine 
cAMP-Dependent Protein Kinase. Extracts of E. coli bearing either plasmid 
6a45 or JC200Z were phospho-labeled in vitro with excess bovine cAMP- 
dependent protein kinase and [y-32p] ATP. The resultant radioactive proteins 
were subjected to SDS-PAGE and detected by autoradiography (Figure 7b). 
The JC200Z-encoded proteins of 182 ,177 ,175 , and 164 KDa were all 
phosphorylated, a s  were the corresponding p6a45 proteins. The 122 KDa 
species, although the most abundant of the fusion proteins, was not 
phosphorylated. This species therefore appears to lack sufficient ADR1 
residues to act a s  a  substrate for the protein kinase, a s  discussed below.
Polyclonal antibodies directed against a  synthetic peptide containing ADR1 
residues 208-231 were used to precipitate the phosphorylated fusion proteins
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Figure 9
a . In  S itu  A ctivity S ta in ing  of P ro te in s  D isplaying B -G alac to s ldase
Activity.
Lanes contain approximately 300 pg of soluble protein from E. coli strain 
M182 (lac*) bearing no plasmid, plasmid p6a t or p6a45 a s  indicated. Purified 
8-galactosidase w as purchased from Sigma; approximately 700 units were 
applied (3 pg). Native PAGE and subsequent staining for 8-galactosidase were 
performed a s  described in Materials and Methods.
b . SDS-PAGE o f B -G alac tosidase  A ctivity-C ontaining F usion
P ro te in s  Iso la ted  from  a  N ative Polyacrylam ide Gel
Crude extracts of E. coli M182 bearing no plasmid or plasmid p6a45 were 
run for reference in the first two lanes. The third lane contains the major band of 
8-galactosidase activity in a . (NB). Numbers to the left of the gel refer to the 
molecular weights of marker proteins in KDa. The 122 KDa fusion protein is 
indicated by the arrowhead on the right.
After excision from the native gel, the band containing the p6a45 active band 
w as soaked overnight in 10% acetic acid. The gel slice w as then washed twice 
for one hour in 1X SDS sample buffer, decanted, and the gel slice was placed 
in a  boiling water bath for 5 minutes prior to insertion into the sample well. The 
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encoded by plasmids p6a45 and JC200Z (Figure 7c). The 182,177, and 175 
KDa fusion proteins were all specifically precipitated by this antibody. The 
analogous proteins from the p6a45 extract were also observed to be 
immunoprecipitated. The 164 KDa fusion protein produced by either JC200Z or 
p6a45 was not immunoprecipitated by this antibody and therefore either does 
not contain sufficient ADR1 sequences to be recognized by the antibody or folds 
in such a  way that interaction with the antibody is blocked. The 122 KDa 
protein, which is not phosphorylated, was also not visible in protein stains of the 
anti-ADR1 antibody immunoprecipitates. These results indicate that the 122 
KDa fusion protein does not contain the ADR1 protein sequences recognized 
by cAPK or the anti-ADR1 antibodies.
A similar immunoprecipitation experiment was conducted using a  polyclonal 
anti-8-galactosidase antibody. All fusion proteins expressed by p6a45, a s  
evidenced by protein staining (Figure 10) and autoradiography (Figure 7d), 
were observed to be immunoprecipitated. These results indicate that although 
only the 182 ,177 ,175  and 164 KDa species were phosphorylated (Figure 7a), 
all five fusion proteins contain sufficient B-galactosidase sequence to be 
recognized by the anti-B-galactosidase antibody.
The approximate locations of the truncation sites resulting in the 122 KDa 
and 164 KDa JC200Z-encoded fusion protein products were postulated by the
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Figure 10
SDS-PAGE A nalysis of p6a45-Encoded Proteins Precipitated by 
Anti-B-G alactosidase Antibody
Silver stained SDS-polyacrylamide gel of anti-B-galactosidase antibody 
precipitates from E. coii RR1 bearing no plasmid or plasmid p6a45. The right 
hand lane contains crude p6a45/RR1 extract. Numbers to the left of the gel 
indicate migration of molecular weight standards in KDa. The p6a45-encoded 
122 KDa fusion protein is indicated on the right.
Antibody precipitations were carried out under native conditions using 
polyclonal anti-IJ-galactosidase antibodies as described in Materials and 
























following reasoning: The smallest and most abundant fusion protein (122 KDa) 
was not phosphorylated nor was it precipitated by the anti-ADR1 antibody. It 
was, however, precipitated by the anti-8-galactosidase antibody and in situ 
activity staining indicated that it did have B-galactosidase activity. B ased on the 
molecular weight derived from SDS-PAGE, the 122 KDa fusion protein was 
estimated to contain 550 fewer amino acids than the full length fusion protein 
which contains 659 ADR1 residues and 1017 B-galactosidase residues. The 
122 KDa species therefore most likely contains only a  small portion of ADR1 
lacking the phosphorylation site at amino acid 230 fused to a whole o r near 
whole functional B-galactosidase protein. The 164 KDa protein was 
phosphorylated, was precipitated by anti-B-galactosidase antibody, but was not 
precipitated by the anti-ADR1 antibody. The truncation site in the 164 KDa 
ADR1 /B-galactosidase fusion protein may lie between residues 208 and 227 of 
ADR1 in order for it not to be recognized by the anti-ADR1 antibody which is 
directed specifically against the 208-231 ADR1 peptide, yet still retain the ability 
to be phosphorylated at serine-230. Results of peptide mapping experiments 
discussed below indicate that phosphorylation of the 164 KDa fusion protein 
occurs solely at residue 230. Alternatively, the SDS-PAGE derived molecular 
weight indicates that the 164 KDa species lacks approximately 170 residues 
indicating that cleavage may occur at a  site to the N-terminal side of residue
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208, yet alter the folding of the resulting protein such that interaction with the 
anti-ADR1 antibody is blocked.
Relative Phosphorylation of ADR1/ and ADRlC/B-Galactosidase Fusion 
Proteins. Previous investigations hypothesized that ADR1 mutant proteins 
which allow ADH2 expression to partially escape  glucose repression are not
32phosphorylated a s  efficiently a s  wild-type ADR1 . This hypothesis w as tested 
using plasmids JC202Z, JC205Z, and JC207Z. These plasmids are identical to 
plasmid JC200Z except they contain the ADR1-2C. ADR 1-5°. and ADR1-70 
mutations, respectively (Figure 5). Extracts of E. coli bearing these plasmids 
were phosphorylated using varying concentrations of bovine cAMP-dependent 
protein kinase and analyzed by SDS-PAGE (Figure 11).
The ADR1-2C. ADR1-5C. and ADR1-7C mutations were found to significantly 
decrease the level of fusion protein phosphorylation relative to wild-type ADR1. 
This trend became progressively clearer a s  the  level of kinase in the 
phosphorylation mixes decreased (Figure 12). In other words, at low kinase 
concentrations the ADR1 protein was a  better substrate for cAPK and w as 
phosphorylated to a  greater extent than were the ADR1-2C, ADR1-50, and 
ADR1-7C proteins. At higher kinase concentrations the ADR1-20 and ADR1-50 
proteins appeared to be phosphorylated to nearly the sam e extent a s  the wild- 
type protein. Thus ADR1 mutations which render ADH2 expression constitutive
64
Figure 11
Relative Phosphorylation of ADR1/, ADR1-26/, ADR1-5C/, and
ADR1-7c /B -G alactosidase Fusion Proteins Using Bovine cAMP-
Dependent Protein Kinase
Autoradiogram of plasmid-bearing E. coli strain M182 extracts 
phosphorylated in vitro using bovine cAMP-dependent protein kinase and 
separated on a  5% SDS-polyacrylamide gel. Extracts of E. coli strain M182 
bearing plasmids JC200Z (ADR1), JC202Z (ADR1-2C), JC205Z (ADR 1-5°), and 
JC207Z (ADR1-7C) were prepared, phospho-labeled and fractionated on an 
SDS-polyacrylamide gel a s  described in Materials and Methods. The ATP 
concentration w as 0.1 mM with a  specific activity of 2.5 X 103 cpm/pmol and the 
concentration of the catalytic subunit of bovine cAMP-dependent protein kinase 

























Graphical Representation of Phosphate Incorporation in the
ADR1 C Fusion Proteins Relative to  the ADR1 Fusion Proteins
Phosphate incorporation w as measured by densitometric scanning and 
integration of the 164 KDa fusion protein bands appearing on the 
autoradiogram in Figure 11. Phosphate incorporation in each fusion protein 
was scaled to the amount of fusion protein present in each labeled band as 
determined by densitometric analysis of the silver stained polyacrylamide gel 
The total amount of phosphate incorporated into the ADR1/0-galactosidase 
fusion proteins at the highest kinase concentration (0.14 pmol U/ pi) w as 
arbitrarily scaled to 1. Each value for the indicated fusion protein species is 


























Figure 12a. 182 KDa Fusion Phosphorylation
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Figure 12b. 177,175 KDa Fusion Phosphorylation
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in yeast also decrease  in vitro phosphorylation of ADR1 by bovine cAMP- 
dependent protein kinase. Since these mutations alter residues within the 
phosphorylation consensus region found between amino acids 227 and 230, 
the serine residue at amino acid 230 most likely serves as the primary 
phosphate acceptor of ADR1 cAMP-dependent phosphorylation.
The presence of a  second ADR1 phosphorylation site was indicated by the 
phosphorylation of fusion proteins produced by plasmid JC207Z. This plasmid 
carries the ADR1-7C mutation and therefore encodes a  fusion protein in which 
the phosphoacceptor serine at amino acid 230 is replaced by a  leucine. 
Although such a  mutation would be expected to eliminate phosphorylation at 
the primary site, it did not completely block phosphorylation of the fusion 
proteins (Figure 11). The 182,177, and 175 KDa ADR1-7c/l3~galactosidase 
fusion proteins were all slightly but significantly phosphorylated (Figs. 11 & 12). 
However, even at high kinase concentrations, the 164 KDa fusion protein w as 
not phosphorylated. It therefore appears that a  secondary phosphorylation site 
exists to the N-terminal side of the primary site at amino acid 230 which is not 
present in the truncated 164 KDa protein. Phosphorylation of this secondary 
site was only detectable at high enzyme concentrations indicating that it is a  
less "preferred" substrate for the cAMP-dependent protein kinase than the 
primary site.
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Peptide Mapping of the ADR1 Phosphorylation Sites. Phosphorylated 
ADR1/ and ADR1c/l3-galactosidase fusion proteins were isolated from SDS- 
polyacrylamide gels and digested with chymotrypsin. The resulting peptides 
were analyzed using native PAGE as  described in Materials and Methods 
(Figure 14).
The 164 KDa fusion protein, the doublet containing the 177 and 175 KDa 
species, and the 182 KDa fusion protein were each excised from lanes 
containing JC200Z (ADR1), JC202Z (ADR1-20), JC205Z (ADR 1-5°) and 
JC207Z (ADR1-70) extracts. The proteins contained in the 182 KDa and 177, 
175 KDa doublet were thought to contain two phosphorylation sites, a  primary 
site at amino acid 230 and an unidentified secondary site, while the 164 KDa 
protein apparently contained only the primary site. Comparison of labeled 
peptides produced by digestion of these two protein species thus allowed 
differentiation between those chymotryptic peptides containing the primary site 
of phosphorylation and those containing the secondary site of phosphorylation.
A synthetic peptide spanning amino acids 222 to 231 of ADR1 was 
phosphorylated and electrophoresed on the mapping gel in both chymotrypsin- 
digested and undigested form a s  indicated in Figure 13. This peptide contained 
the putative primary phosphorylation site at amino acid 230 and thus served a s  
a  standard for comparison to the ADR1 fusion protein digest. The undigested
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Figure 13
ADR1 Amino Acid S eq u en ce  Surrounding the Putative
Phosphorylation S ite at Amino Acid 230.
L, ADR1-7®  
A
K, AD R1-5p S ,  ADR1-2®
201
N R T T A N T R R
k k
The sequence of the undigested synthetic peptide is boxed. Bold arrows 
beneath the sequence indicate possible chymotryptic cleavage sites, circles 
represent serine residues likely to serve a s  phosphoacceptors based  on 
homology to known sites of cAMP-dependent protein kinase recognition 
sequences. Predicted alterations in primary structure caused  by the ADR1C 
mutations a re  indicated above the single letter amino acid abbreviations. The 
bold line beneath residues 226-231 indicates the presum ed limit digest product 
of the ADR1/l3-galactosidase fusion containing the primary phosphorylation site. 
The ADR1-2C limit digest product was predicted to contain residues 226-239 
due  to loss of the chymotryptic site after phenylalanine331 . Calculated charge 
to frictional coefficient ratios of the putative chymotryptic digest products are 
approximated in calculations presented in Appendix D.
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Figure 14
Peptide Mapping of the Primary Phosphorylation Site in ADR1
Autoradiogram of a  50% polyacrylamide gel (pH 3) containing 
phosphorylated peptides produced by chymotryptic digest of ADR1/G- 
galactosidase fusion proteins a s  described in Materials and Methods. Digests 
of the 182 KDa fusions, the 177 and 175 KDa fusions, and the 164 KDa fusions 
appear in the lanes indicated. The top of each lane is labelled according to the 
ADR1 mutation it contains. Lanes containing digested and undigested synthetic 
ADR1 peptide standards are so  indicated and are described in Materials and 
Methods. The Control lane contains a  chymotrypsin-digested phosphorylation 
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peptide, which was designed a s  a  chymotryptic digest product, ran near the 
front on the mapping gel (Figure 14). After digestion its mobiiity decreased, 
presumably a s  the N-terminal four residues were removed to produce the limit 
digest product defined by residues 227-231.
Digestion of the ADR1/8-galactosidase fusion proteins in the 182,177 -175, 
and 164 KDa bands revealed three major phospho-labeled peptides, the 
slowest migrating of which co-migrated with the synthetic peptide limit digest, in 
both the 177,175 KDa doublet and the 164 KDa species. The peptide with the 
greatest mobility appears faintly in the 164 KDa digest lane (Figure 14) and  is 
presumed to be a  partial digest product which contains the primary 
phosphorylation site at serine-230. This conclusion is supported by the fact that 
both the slowest and fastest migrating peptides of the ADR1 182 and 177-175 
KDa digests are not present in the digests of the ADR1-7C 182 and 177-175 
KDa fusion proteins. In contrast, the peptide having an intermediate mobility in 
the ADR1 182 and 177-175 KDa digest lanes is present in all the ADR1C 182 
and 177-175 KDa fusion protein digest lanes. Because the ADR1 -7C fusion 
protein cannot be phosphorylated at residue 230, this intermediate band must 
be a  peptide containing a  secondary phosphorylation site. The absence of this 
intermediate-mobility peptide in all of the 164 KDa digest lanes indicates that it 
is derived from sequences on the N-terminal side of residue 230. It can be
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concluded that under these conditions ADR1 is selectively phosphorylated at 
two specific sites.
The ADR1-2C mutation, which eliminates the chymotryptic cleavage site at 
amino acid 231, resulted in a  decrease in the mobility of the partial and limit 
digest phosphopeptides containing residue 230 due to the decreased charge 
to frictional coefficient ratio caused by the extension of the peptide (see 
Appendix D for these calculations). The ADR1-5C mutation, on the other hand, 
caused an increase in the mobility of these phosphopeptides relative to the 
ADR1 digest. Although the ADR1-50 mutation does not alter any chymotrypsin 
sites directly, the change from an arginine to a  lysine within the labeled 
peptides apparently causes an alteration in mobility. It should be noted that the 
ADR1-2C partial digest peptide (having the greatest mobility) and the ADR1-5C 
limit digest peptide (having the lowest mobility) both comigrated with the 
peptide containing the secondary site. These ADR1-2C and ADR1-5C peptides 
are present in the 164 KDa digest patterns further supporting that they are 
derived from the peptide containing the primary site of phosphorylation. The 
partial digest peptides containing residue 230 varied in their autoradiogram 
signal intensity relative to the limit digest peptide from digest to digest, 
supporting the conclusion that they result from partial proteolysis of the whole 
fusion proteins. Chymotryptic digestion and peptide analysis of the 182 KDa
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ADR1/ and ADR10/ B-galactosidase fusion proteins gave similar mapping 
results to the results obtained using the 177,175 KDa protein (Figure 14). 
Unfortunately the ADR1-2C 182 KDa digest was lost during the procedure .
Phosphorylation of ADR1/and ADRIC/B-Galactosidase Fusion Proteins by 
Y east cAMP-Deoendent Protein Kinase. Purified yeast cAMP-dependent 
protein kinase catalytic subunit C1 encoded by the TPK1 locus w as also used to 
phosphorylate the fusion proteins in vitro. The fusion proteins were 
phosphorylated by yeast cAPK in a  m anner similar to that observed with the 
bovine kinase. As shown in Figure 15, the ADR1, ADR1-2C and ADR1-50 
fusion protein bands of 182 ,177 ,175 , and 164 KDa were labeled by the C1 
kinase while the ADR 1-7^ fusion band of 164 KDa was, as seen  with the 
bovine kinase, not phosphorylated. Phosphorylation was specifically blocked 
by the addition of purified yeast cAMP-dependent protein kinase regulatory 
subunit (R encoded by BCY1).
Although the  yeast and bovine kinases were observed to phosphorylate the  
sam e fusion protein species, the two enzymes were found to differ in their 
apparent specificities for the ADR1-2C and ADR1 -5C proteins. Using the bovine 
kinase the relative incorporation of phosphate was ADR1 > ADR1-5C > ADR1-2C 
> ADR1-7C. In contrast the yeast kinase phosphorylated ADR1 > ADR1-20 > 
ADR1-50 > ADR1-7C (Figure 16). On this basis it is concluded tha t yeast C1
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kinase phosphorylates the sequence RRASSS (ADR1-20) better than the 
sequence RKASFS (ADR1-5C), while the mammalian kinase phosphorylates 
the sequence RKASFS better than the sequence RRASSS. The two kinases 
may therefore differ in their substrate specificities.
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Figure 15
Relative Phosphorylation of ADR1/, ADR1-20/, ADR1-50 /, and 
ADR1-7C/B-G alactosldase Fusion Proteins Using Yeast cAMP-
Dependent Protein Kinase C1
Autoradiogram of plasmid-bearing E. coli strain 4562 extracts 
phosphorylated in vitro using the purified yeast kinase C1 as described in 
Materials and Methods. In those lanes indicated (+) purified yeast regulatory 
subunit R fBCYl) was added to a  concentration which was 10 fold higher than 









Figure 16. Substrate Sp ecificities of the Y east and Bovine K inases
a. Graphical representation of phosphate incorporation in the 164 
KDa ADR1/, ADR1-2C/, and ADR1-5c //ft-ga lactosid ase  fusion  
proteins using y ea st cAM P-dependent protein kinase C1. P h o sp h a te  
incorporation was m easured by densitometric scanning and integration of the 
164 KDa fusion protein bands appearing on the autoradiogram in Figure 15. 
Phosphate incorporation in each fusion protein was scaled to the amount of 
fusion protein present in each labeled band a s  determined by densitometric 
analysis of the silver stained polyaciylamide gel. The total amount of 
phosphate incorporated into the 182 ,177 ,175 , and 164 KDa ADR1/8- 
galactosidase fusion proteins was arbitrarily scaled to 1. The values for the 
relative phosphorylation of the ADR1, ADR1-2C, and ADR1-50 fusion protein 
species are presented as the fraction of that total.
b. Graphical representation of phosphate incorporation In the 164 
KDa ADR1/, ADR1-2®/, and ADR1-5c //B -ga lactosid ase  fu sion  
proteins using bovine cAMP>dependent protein kinase. E xpanded  
graph of phosphate incorporation into the 164 KDa fusion protein by 0.003 pmol 














In the model proposed by Denis and Gallo32 the glucose repression of 
ADH2 is mediated in part by a  glucose-dependent reduction in the activity of the 
transcriptional activator ADR1. Based on the characterization of the ADR1 -5° 
mutation, ADR1 activity w as proposed to be reduced during fermentative growth 
a s  a  result of cAMP-dependent phosphorylation. The results of the work 
presented herein strongly support the involvement of cAMP-dependent 
phosphorylation in the regulation of ADR1 activity.
Using ADR1/3-galactosidase fusion proteins expressed in E coli it was 
demonstrated that in vitro mammalian cAPK phosphorylates ADR1 at two 
distinguishable sites. A phosphorylated chymotryptic peptide was found to 
comigrate with a  phosphorylated chymotryptic fragment derived from a  synthetic 
peptide containing ADR1 residues 227-231. The mobility of the labeled peptide 
on a  peptide mapping gel w as altered when it contained either the ADR1-2C or 
ADR1-50 sequences. Other peptides presumed to be partial chymotrypsin 
digest products also displayed altered mobilities. Furthermore, when the 
peptide contained ADR1-7C sequences (in which the phosphoacceptor serine 
at residue 230 is replaced by leucine), phosphorylation was eliminated 
(compare phosphorylation of ADR1- and ADR1-7c-peptides in the 164 KDa
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digests of Figure 14). These data  strongly indicates that mammalian cAPK 
recognizes ADR1 residues 227-231, with serine-230 serving a s  the 
phosphoacceptor.
The results also indicate the existence of a  second in vitro phosphorylation 
site in ADR1 which is weakly recognized by yeast and bovine cAPK relative to 
the primary phosphorylation site at serine-230. The 182,177, and 175 KDa 
ADR1 -7c/8-galactosidase fusion proteins were phosphorylated in vitro despite 
the fact that in these  mutant proteins the phosphoacceptor serine at residue 230 
is replaced by a  leucine residue. Furthermore, the 164 KDa ADR1/, ADR1-20/, 
and ADR1-5c/f3-galactosidase fusion proteins were all phosphorylated in vitro, 
while the ADR1-7C 164 KDa fusion protein w as not, indicating that the 164 KDa 
fusions lack the secondary phosphorylation site. Finally, peptide mapping of 
the 182,177, and 175 KDa ADR1-7C/8-galactosidase fusion protein digests 
revealed a  single phosphorylated peptide which is present in digests of all the 
comparable ADR1, ADR1-2C, and ADR1-5C fusion proteins. This peptide, which 
w as not observed in the 164 KDa digests, is presumed to encom pass a  
secondary phosphorylation site in ADR1 which is N-terminal to the primary 
phosphorylation site lying betw een residues 227-231.
ADR1 contains four regions in addition to the one between residues 227- 
231 which are homologous to the cAPK phosphorylation consensus sequence*
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and could serve a s  the second phosphorylation site. Since the 164 KDa fusion 
proteins appeared to lack the secondary phosphorylation site, it w as 
hypothesized that the secondary phosphorylation site occurs at a  position N- 
terminal to the primary phosphorylation site at serine-230. Consistent with this 
hypothesis, the putative secondary phosphorylation sites at threonine-226, 
serine-211, serine-180, and serine-170 identified by homology to the cAPK 
phosphorylation consensus sequence are N-terminally located with respect to 
the primary phosphorylation site at serine-230. The putative phosphoacceptor 
threonine-226 in the sequence Lys-Lys-Leu-Thr-Arg lies just N-terminal to the 
primary phosphorylation site and occurs on the sam e chymotryptic peptide. 
Since the 164 KDa ADR1-7C fusion protein digest contained no phosphorylated 
peptides, threonine-226 can not be the the secondary site of in vitro 
phosphorylation that was observed.
The likelihood of the other sites serving a s  potential phosphorylation sites 
w as explored by examining results of previous studies on the kinetics of the in 
vitro phosphorylation of synthetic peptides. Granot and colleagues73 found 
that the presence of a  proline residue adjacent to the phosphoacceptor serine, 
a s  in the putative site located between residues 209-212 (Arg-Lys-Ala-Ser-Pro), 
decreased the kcat/Km ratio of mammalian cAPK by -5  X 106 relative to an 
ADR1-like peptide. In other words, under identical labelling conditions the
*Arg-Arg-X-Ser-Y, where Y tends to be hydrophobic and X is any amino acid.
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proline-containing peptide occurred at a  rate ~10'6 that of the ADR1-like 
peptide. It thus appears unlikely that this site would be phosphorylated to any 
measurable extent in vitro in ADR1 . Of the two remaining sites, the site within 
residues 177-181 (Arg-Lys-Asn-Ser-Ata) is most homologous to the cAPK 
consensus phosphorylation sequence and is therefore more likely to serve as a 
substrate for cAPK than is the site between residues 167-171 (Lys-Lys-Val-Ser- 
Arg). Kemp and colleagues35 have shown that the two N-terminal arginine 
residues within the phosphorylation consensus sequence are crucial to 
substrate recognition by cAPK. Substitution of the N-terminal arginine with 
lysine in a  synthetic peptide resulted in an approximately 90-fold increase in the 
Km of phosphorylation. In contrast, replacement of the C-terminal arginine with 
lysine resulted in a  16-fold increase in the Km. On this basis the 
phosphorylation site between residues 177-181 (Arg-Lys-Asn-Ser-Ala) might 
be expected to serve a s  a  better substrate for cAPK than the site between 
residues 167-171 (Lys-Lys-Val-Ser-Arg). The results of previous kinetic 
analyses using synthetic peptides a s  substrates for in vitro phosphorylation by 
cAPK therefore suggest that the observed secondary ADR1 phosphorylation 
site w as serine-180. It should be emphasized that this prediction is based  
solely on the in vitro kinetic properties of the bovine cAPK and does not 
consider the possible effects which ADR1 tertiary structure may have on the in
vitro phosphorylation of serine-180. Further experiments employing two- 
dimensional peptide mapping techniques and/or sequencing of the relevant 
phosphopeptide would be required to unambiguously identify the secondary 
site of phosphorylation in ADR1.
The identification of a  second site in ADR1 which is phosphorylated in vitro 
brings up the interesting possibility that ADR1 is phosphorylated at more than 
one site in vivo. The yeast ribosomal protein S10 has been shown to be 
multiply phosphorylated74, a s  has the large T antigen of simian virus 4075. In 
the ca se  of large T antigen only one of the phosphorylation sites has been 
demonstrated to functionally affect the protein76, while in the S10 protein 
phosphorylation by cAPK appears to play no regulatory function74.
Replacement of serine-180 with an alanine residue using site directed 
mutagenesis would help to clarify whether this putative secondary 
phosphorylation site is involved in the regulation of ADR1.
The yeast and mammalian (bovine) cAPK were observed to have slightly 
different substrate specificities when used in the in vitro phosphorylation of the 
fusion proteins. The yeast kinase phosphorylated the sequence Arg-Arg-Ala- 
Ser-Ser-Ser (ADR1-2C) to a  greater extent than the sequence Arg-Lys-Ala-Ser- 
Phe-Ser (ADR1-5C) during the incubation period of the assay, in contrast, the 
bovine kinase had the opposite preference, phosphorylating the sequence Arg-
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Lys-Ala-Ser-Phe-Ser (ADR1 -5C) to a  greater extent than the sequence Arg- 
Arg-Ala-Ser-Ser-Ser (ADR1-2*5). These results could arise from two quite 
different phenomena. First, although the affinity of the enzym es for each of the 
two different sequences could be nearly the sam e, the stiochiometries of 
incorporation may be different. In other words, the two enzymes may share 
similar Michealis constants (Km's) for the sequence Arg-Arg-Ala-Ser-Ser-Ser, 
but the number of serines phosphorylated by the two enzymes may differ. 
Alternatively, the difference observed in the levels of phosphate incorporation 
may simply reflect that the kinases differ in their Km's for the two 
phosphorylation sequences. Differences in the substrate specificities of the 
yeast and mammalian kinases might result from minor differences in their 
respective active sites, white alterations in the stoichiometry of phosphorylation 
would require that more gross functional differences exist between the two 
enzymes. The yeast C1 catalytic subunit and mammalian catalytic subunits are 
only approximately 50% homologous in the conserved C-terminal 310 amino 
acids49, indicating that either explanation may be responsible for the observed 
differences in substrate specificities. Further studies examining the 
stoichiometry and kinetics of phosphorylation of the sequence Arg-Arg-Ala-Ser- 
Ser-Ser by these  two enzym es are required to clarify this issue.
The demonstration that ADR1 c/l3-galactosidase fusion proteins were less
8 8
amenable to cAMP-dependent phosphorylation than were ADR1/I3- 
galactosidase fusion proteins strongly supports the hypothesis that 
phosphorylation is physiologically significant in the regulation of ADR1 activity. 
Both the yeast and bovine cAPK catalytic subunits phosphorylated fusion 
proteins containing the ADR1C amino acid substitutions poorly relative to fusion 
proteins containing the ADR1 sequences. In vivo the ADR1C proteins may 
therefore partially bypass glucose-dependent phosphorylation, in turn allowing 
them to activate ADH2 transcription during glucose repression.
Krebs and colleagues77 have suggested that in order for a  physiological role 
for cAMP-dependent phosphorylation to be considered valid the following five
criteria must be met:
1. The protein must be phosphorylated by cAPK in vitro.
2. In vitro phosphorylation must lead to a  modified function.
3. A stoichiometric correlation must exist between in vitro 
phosphorylation and modified function.
4. Phosphorylation of the sam e protein must be demonstrated in vivo in 
response to a  cAMP signal.
5. Modified function must be demonstrated in response to a  cAMP signal 
in vivo.
The first of these criteria has been satisfied by the demonstration that ADR1 
is phosphorylated at two distinguishable sites in vitro by cAPK. The second 
and third criteria proposed by Krebs et al., a s  they pertain to ADR1, concern 
correlating the stoichiometry of in vitro phosphorylation with a  decreased ability
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to activate transcription of ADH2. Constitutive ADR1C mutants, which have an 
increased ability to activate ADH2 transcription during glucose repression, were 
less amenable to in vitro phosphorylation by cAPK than was the wild-type 
ADR1 protein, which is unable to activate transcription during glucose 
repression (Figures 11 and 15). It thus appears that the degree of in vitro 
phosphorylation of mutant ADR1C proteins can be correlated with a  known 
modified function in vivo. It is significant that strains carrying the ADR1-5C 
mutation have slightly higher ADH II activities than strains carrying the ADR1-7C 
mutation, although the ADR1-50 protein was observed to be phosphorylated at 
serine-230 while the ADR1-7C protein w as not. These data  do not necessarily 
preclude the possibility that a  stoichiometric relationship between ADR1 
phosphorylation and ADR1 activity exists. The ADR1-5C and ADR1-70 proteins 
may have tertiary or quaternary structures which are significantly different than 
the wild-type ADR1 protein. These structural differences may affect their ADR1 
activities independently of any effect which they have on the phosphorylation 
state. The substitution of a  leucine for the phosphoacceptor serine in the ADR1- 
7° protein may, for instance, have two opposing effects on ADR1 activity- it may 
activate the protein by eliminating phosphorylation at residue 230, but it may 
also diminish its ability to activate transcription by altering the tertiary structure 
of the protein. Similarly, the substitution of a  lysine for an arginine within the
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phosphorylation consensus sequence in ADR1-5C may not only decrease  its 
ability to act a s  a  cAPK substrate, but also enhance its function as a  
transcriptional activator by causing a  beneficial alteration in the protein 
structure. Both of these scenarios imply that the phosphorylation sequence 
around serine-230 plays a  role in ADR1 function even when not 
phosphorylated, a s  is indicated by the results of Bemis and Denis23 discussed 
below. Without knowing the effect the ADR1C mutations have on the structure of 
the ADR1 protein it is impossible to attribute their phenotypes solely to the effect 
which they have on the phosphorylation state  of the protein. Determining 
whether there is a  stoichiometric correlation between ADR1 phosphorylation 
and ADR1 activity will require determination of the phosphorylation state of 
wild-type ADR1 during repressed and derepressed growth conditions. Criteria 
2 and 3 may be more directly tested if an in vitro assay for ADR1 -mediated 
transcriptional activation becom es available.
Criteria 4 and  5, as  they pertain to ADR1, address the question of whether a
cAMP signal modifies the in vi'vo activity of the ADR1 protein. Recent genetic
experiments indicate that ADR1 activity is responsive to cAMP-dependent
phosphorylation in vivo (C. Denis, personal communication). As mentioned in
the  Introduction, yeast cAPK is composed of a  catalytic subunit and a  cAMP-
responsive regulatory subunit49,50. Three genes encode catalytic subunits,
TPK1. TPK2. and TPK3. while a  regulatory subunit is encoded by a  single gene
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designated BCY1. The ADH II activities of strains containing only one of the 
catalytic subunits were compared to strains in which the gene coding for the 
regulatory subunit had been disrupted fbcvh . Strains with bcvl disruptions, 
lacking a  functional regulatory subunit, were expected to have unregulated 
kinase activity, while those with the BCY1 allele were expected to have had 
cAMP-dependent kinase activity. ADH2 derepression w as shown to decrease 
ten to fifteen fold in two out of three strains with unregulated kinase activity 
(Table 5). While the three catalytic subunits have been shown to be able to 
functionally substitute for one another, there is some indication that they differ in 
their substrate specificities. For example, unregulated TPK3 kinase activity has 
no effect on other non-fermentative processes50 or on ADH2 derepression, 
suggesting that the catalytic subunit encoded by TPK3 may be less active or not 
recognize ADR1 and other substrates during non-fermentative growth.
Denis next used strains containing the ADR1-5C and ADR1-7C in an effort to 
show that the effect of unregulated kinase on ADH2 expression was mediated 
through the ADR1 protein. He reasoned that ADR 1-5° would be more sensitive 
to unregulated kinase activity than ADR 1-7° based on the fact that the latter 
mutation encodes a  protein lacking the phosphoacceptor serine. Under 
derepressed growth conditions unregulated TPK1 kinase activity decreased 
ADH II activity in the ADR1-5C strain 4.4-fold, while it decreased ADR1-7C
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dependent activity 2.4-fold (Table 5). Although less dramatic, the glucose 
repressed ADH II activities show a  similar trend with the ADR1-5C strain 
decreasing 2.2-fold compared to 1.5-fold for the ADR1-7C strain. Unregulated 
TPK3 kinase activity did not affect ADH II expression under derepressing 
conditions, consistent with the aforementioned suggestion that this kinase is 
less active or recognizes ADR1 poorly during non-fermentative growth. Under 
glucose-repressed growth conditions ADR 1-5° -dependent ADH II activity was 
decreased 4.7-fold by unregulated TPK3 kinase activity, while the ADR1-7C - 
dependent activity decreased only 1.4-fold.
Taken together the in vitro phosphorylation studies presented in this work 
and the genetic analysis performed by Denis clearly demonstrate that ADR1 
function is modified by cAMP-dependent phosphorylation in vivo.
Results previous to this work indicated that the glucose repression of ADH2 
occurs at the level of transcription16. The isolation24 and characterization27,32 of 
dominant constitutive ADR1C mutations which allow ADH2 expression to 
partially escape glucose repression implies that the ADR1 protein is responsive 
to a  glucose repression signal.
There are two basic mechanisms by which a glucose repression signal could 
affect a  regulatory protein required for transcription of ADH2. The first would be 
to alter the cellular concentration of the ADR1 protein by affecting its
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Table 5.
Effect of BCY1 G ene Disruption on APH2 E xpression
Strains used in the preparation of this table are described in detail in the 
reference from which it was taken (Cherry et al.27). ADH II activities were 
determined as described16 following growth of cultures overnight at 30° C. 
Culture mediums contained YEP medium (2% yeast extract, 1% Bacto-peptone, 
20 mg/L adenine and uracil) supplemented with either 8% glucose or 3% 
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transcription, translation, or rate of degradation. The E. coli lamda phage 
provides an interesting example of a  transcriptional control mechanism by 
which the cellular concentration of the lambda repressor is autoregulated78,93. 
Transcription of the lytic genes and the gene encoding the lambda repressor 
(cl) are repressed by the lambda repressor protein when its concentration is 
high. When the cellular concentration of lambda repressor becomes low, 
repressor binding is reduced and transcription of the ci gene is stimulated. 
Cellular signals can also modulate the cellular concentration of regulatory 
proteins translationally, a s  has been demonstrated for the GCN4 protein in
a n
yeast . GCN4 is a  positive regulatory protein required for transcription of 
amino acid biosynthetic genes in yeast79. The cellular signal, amino acid 
starvation, removes a  block on the translation of the GCN4 protein and causes 
an increased rate of translation80. The resulting increase in GCN4 protein 
concentration allows transcriptional activation of approximately 50 biosynthetic 
genes. Although there are currently no examples of a  cellular signal which 
causes an increased rate of regulatory protein degradation, several enzym es in 
yeast are known to be preferentially degraded proteolytically in response to the 
addition of glucose to the growth medium. In the case  of the gluconeogenic 
enzyme fructose-1,6-bisphosphatase glucose induced inactivation is a t least 
partially mediated by a  cAMP-dependent phosphorylation step81,82. There
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appears to be a  direct correlation between the degree of subunit 
phosphorylation, which inactivates the enzyme, and the rate of its subsequent 
proteolytic degradation01,02,41. This mechanism, termed catabolite inactivation, 
may also be used by the cell to selectively degrade regulatory proteins which 
are not required during growth on fermentable carbon sources, such a s  ADR1.
The second way in which a  glucose repression signal could affect ADR1 
activity is by inducing a  transition of the protein from an active state to an 
inactive state. By regulating the activity of the protein rather than its synthesis or 
degradation, such a  mechanism would offer the advantages of being faster and 
more energetically economical, since no de novo protein synthesis would be 
required. In E. coli transcription of several glucose repressed operons requires 
that the catabolite activator protein (CAP) be bound to operator sequences03*06. 
CAP must bind cAMP before it can bind to DNA and activate transcription. In E. 
coli intracellular cAMP levels are increased in the absence of glucose. When 
cells are grown in the absence of glucose, cAMP levels are elevated and CAP 
is activated. Thus the glucose repression of operons such a s  lac and ara  is 
mediated through low cAMP levels which prevent CAP from activating 
transcription. The E. coli lac repressor provides another example in which a  
cellular signal modifies the  activity of a  regulatory protein. This negative 
regulatory protein binds to the lac operator and sterically blocks transcription of
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the lac operon83. When ceils are exposed to lactose an inducer is produced, 
allolactose, which is bound by the lac repressor causing its release from the 
operator.
In the examples discussed thus far the cellular m essengers interact directly 
with regulatory proteins which bind to DNA and affect transcription. A cellular 
signal may also interact with a  regulatory protein not directly involved with DNA- 
binding, but which eventually results in an effect on transcription. The galactose 
metabolism system in yeast, for example, is largely controlled by the positive 
regulatory protein GAL4 and the negative effector GAL8087. Transcription is 
dependent on binding of the GAL4 protein to upstream activating sequences 
(UAS's) located upstream from the site of transcription initiation88,89. In the 
absence of galactose the GAL80 protein binds to the GAL4 protein and blocks 
its activator function90. Since GAL80 does not bind to the UAS's and binding of 
GAL80 to GAL4 does not disrupt GAL4 binding to DNA89, it is presum ed that 
GAL80 m asks some functional region of GAL4 which normally interacts with the 
transcriptional complex. In the presence of galactose, GAL80 is altered such
QA
that it no longer binds to GAL4 and transcription is activated . It is unclear 
whether GAL80 interacts directly with galactose, but it is evident that some 
cellular signal indicating the availability of galactose is transmitted via protein* 
protein interactions to activate transcription of the genes required for galactose
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metabolism.
Several studies suggest that ADR1 is not transcriptionally or translationally 
controlled in response to a  glucose repression signal. ADR1 mRNA has been 
demonstrated to be constitutively synthesized independent of the carbon source 
in the growth medium32. ADR1C mutations allow ADH2 transcription to partially 
escape glucose repression. The characterization of these  mutations a s  single 
amino acid substitutions32,27 suggests that ADR1 is translated under 
fermentative conditions. Therefore if the cellular concentration of ADR1 is 
controlled, it must occur through a  post-translational mechanism.
Although it appears quite clear that the glucose repression of ADH2 is in part
mediated by phosphorylation of the ADR1 protein, the mechanism by which
phosphorylation reduces the ability of ADR1 to activate ADH2 transcription
remains unclear. A recent report by Bemis and Denis23 in which they studied
the effects of various ADR1 gene truncations on ADH2 expression clarifies the
role which the phosphorylation region plays in ADR1 function. Strains
expressing only the N-terminal 220 amino acids of ADR1 (ADR1-220) did not
allow ADH2 to escape glucose repression, although the truncated protein was
capable of activating ADH2 under derepressing conditions. Increased
expression of ADR1-220 did not allow ADH2 expression to escape glucose
repression. In contrast, increased expression of any ADR1 proteins containing
the phosphorylation site at serine-230 did allow ADH2 expression to bypass
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glucose repression. From these data it appears that the phosphorylation site at 
serine-230 is required for ADR1 to bypass ADH2 glucose repression, but is not 
required for activation of ADH2 transcription during derepressed growth.
How can bypassing glucose repression of ADH2 require the ADR1 
phosphorylation region, yet not allow ADH2 expression to escape glucose 
repression when removed? Bemis and Denis23 suggest that this apparent 
paradox results from the decreased ability of the ADR1-220 protein to activate 
transcription a s  compared to proteins which contain the phosphorylation region. 
They found that the ADR1-220 protein w as 2-3 fold less active than proteins 
containing the N-terminal 253 or 272 amino acids of ADR1 (ADR1-253 and 
ADR1-272) under derepressing conditions. These results indicate that the 
phosphorylation region, while negatively affected by phosphorylation during 
glucose repression, plays a  positive role in ADR1 function. The ADR1 -220 
protein may be able to activate transcription under derepressed conditions 
because other proteins necessary for ADH2 transcription are present and 
active. Under glucose growth conditions increased expression of ADR1-220 
does not allow glucose repression to be bypassed because, unlike larger ADR1 
proteins, this less active truncated ADR1 protein requires other factors which 
are present only during derepression. Thus it appears that phosphorylation 
does not wholly inactivate ADR1, but merely diminishes the positive role which
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the phosphorylation region plays in ADR1 function.
Of the many positive roles it could play, the phosphorylation region may 
facilitate the binding of the ADR1 protein to DNA. The DNA-binding zinc finger 
motif found between residues 99-155 appears to be necessary but not sufficient 
for binding of ADR1 to the ADH2 upstream sequences (E.T. Young, personal 
communication) indicating that other regions of the protein are necessary. 
Simian virus 40 large T antigen, a  protein involved in viral gene regulation and 
replication, has been suggested to be regulated through a phosphorylation 
mechanism76. When dephosphorylated, large T antigen binds to the viral origin 
of replication in vitro with several-fold higher affinity than does the 
phosphorylated protein. Phosphorylation may play a  similar role in the DNA- 
binding properties of ADR1. Since 24% of the amino acids between the C- 
terminal zinc finger and the primary phosphorylation site at amino acid 230 are 
basic residues, while only 4% are acidic (18 of 75 versus 4 of 75), it is tempting 
to speculate that the overall basic nature of this region aids DNA binding 
through electrostatic attraction. Addition of an acidic phosphate group, by 
decreasing the positive character of the region, may diminish such an attraction. 
Deletion of the basic region, a s  in the ADR1-220 protein discussed above, 
would also be expected to diminish ADR1 activity. The first step  in testing this 
hypothesis would be to determine whether the in vitro phosphorylation of
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ADR1 affects its ability to bind to the ADH2 UAS.
The phosphorylation region may also be involved in the transcriptional 
activation properties of ADR1. If ADR1 contacts a  protein in the transcription 
complex directly through the phosphorylation region, phosphorylation may 
disrupt such a  contact. Alternately, the phosphorylation region could contact 
another protein which is required for stimulation of transcription, but which is not 
directly involved in the transcriptional machinery. Yeast regulatory proteins 
GAL4 and GCN4 have been suggested to activate transcription by contacting 
the transcriptional machinery through acidic domains91,92. The basic 
phosphorylation region of ADR1, in order to play a  role in transcription 
activation, may require contact with a  "helper" protein which contains the 
necessary acidic domain. To be consistent with the results of the ADR1 
truncation studies performed by Bemis and Denis discussed above, the helper 
protein must also either interact with ADR1 through regions other than the 
phosphorylation region around serine-230 or not be absolutely required for 
ADR1 function during derepression.
Finally, the phosphorylation region could be important to ADR1 
oligomerization. ADH II activities in ADR1C. adr1-x heterologous diploid strains 
suggest that ADR1 monomers interact with one another to activate transcription 
of ADH2 (C. Denis, personal communication). In addition, the palindromic
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nature of the ADH2 DNA binding site suggests that a  symmetrical oligomer is 
required for binding. Multimers of ADR1 may have better DNA binding or 
transcriptional activation properties than do monomer ADR1 molecules. A good 
example of the possible effects of phosphorylation on oligomerization is 
provided by glycogen phosphorylase, the enzyme which catalyses the first step 
in glycogen metabolism. The transition between an active dimer and a  less- 
active monomer has been suggested to be controlled by the opposing actions 
of phosphorylase kinase and phosphorylase phosphatase44.
Several lines of evidence indicate that while phosphorylation of ADR1 at 
serine-230 is responsible for some of the observed decrease  in ADR1 activity 
during glucose repression, there must exist other factors which contribute to the 
glucose repression of ADH2. The ADH II activity in ADR1-7Q-containino strains 
w as still decreased by unregulated kinase activity, despite the absence  of the 
phosphoacceptor serine at amino acid 230. This data implies that cAMP- 
dependent phosphorylation occurs at another site in ADR1 or that 
phosphorylation of some other factor is important to glucose repression. 
Furthermore. ADH2 expression in strains carrying any of the ADR1C mutations 
never completely bypasses glucose repression (Table 1). Similarly, increased 
dosage of the ADR1 gene allows ADH2 expression to significantly escape  
glucose repression, yet glucose repression of ADH2 is still evident even when
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ADR1 is present at 80 c o p ie s . Factors other than ADR1 must therefore be 
involved in the glucose repression of ADH2.
At least two other genes with pleiotropic action are known to be required for 
ADH2 expression, CCR1 and CCR418'21. Defects in either of these genes 
decrease the activities of a  number of gluconeogenic enzym es which are 
glucose repressed. The CCR1 and CCR4 proteins may therefore be involved in 
the general transmission of a  glucose repression signal. Genetic analysis has 
shown that CCR1 acts through or with ADR1 to activate ADH2 transcription21. 
CCR1 encodes a  protein kinase21, but appears not to act through the primary 
phosphorylation site at amino acid 230 since truncated ADR1 proteins lacking
oo
this site remain sensitive to defects in the CCR1 gene . CCR1 may affect 
phosphorylation of ADR1 at some other site either directly or indirectly or may 
act on som e other protein required for the derepression of glucose-repressed 
genes. The other positive regulatory element, CCR4, is thought to act 
independently of ADR1 at sequences downstream of the TATA promoter 
element in ADH294. Because CCR4 is a  pleiotropic effector it may comprise 
part of a  general transcription complex which is sensitive to a  glucose 
repression signal. There exists genetic evidence that CCR4 is inactivated 
during glucose repression by the action of two negative effectors, CRE1 and 
CRE221. The cellular signals which CRE1 and CRE2 respond to and the
mechanism of their action on CCR4 is unknown.
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Much work remains if the role of phosphorylation in ADR1 regulation is to be 
fully understood. Among the most pressing experiments are  determining the in 
vivo phosphorylation state of the ADR1 protein during repressed and 
derepressed growth conditions, the effect of ADR1 phosphorylation state on 
ADRVs DNA binding properties, and using site directed m utagenesis to 
determine the possible significance of the putative secondary phosphorylation 
site. More long-term goals should be directed toward gaining a  better 
understanding of how phosphorylation molecularly affects the interaction of 
ADR1 with DNA or other proteins of the transcription complex.
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Appendix A
Small s c a le  plasm id prep
(adapted from H. C. Birnboim and J. Doly (1979) Nucleic Acids Res. 7,1513.)
1. Grow 1.5 ml cultures overnight in L broth (10 g tiyptone, 5 g yeast extract, 5 g 
NaCI
per liter) supplemented with appropriate antibiotic (ampicillian to 50 pg/ml).
2. Pellet cells by centrifugation for 1 minute in microcentrifuge tubes.
3. Decant L broth and air dry pellet by inversion on absorbant towels. Dried 
pellets should be loosened by vortexing two tubes together prior to next 
step.
4. Add 100 pi cold lysozyme solution (25 mM Tris-CI, pH 8 ,1 0  mM EDTA, 50 
mM glucose, 2 mg/ml fresh lysozyme), mix thoroughly, and incubate on ice 
10-30 minutes.
5. Add 200 pi NaOH-SDS (0.2 N NaOH, 1% SDS, freshly prepared by mixing 
1 ml 1N NaOH, 0.5 ml 10% SDS, 3.5 ml water) and mix by vortexing.
Incubate on ice 5 minutes.
6 . Add 150 pi 3M sodium acetate, pH 4.8 and vortex in inverted position for 10 
seconds at low speed . Vigorous mixing will result in contamination with 
genomic DNA. Incubate on ice 20-60 minutes.
7. Centrifuge at 4° C. for 10 minutes and remove supernatant to a  fresh 
microtube (avoiding the pellet) using a  1 ml micropipet. This supernatant 
contains the plasmid DNA.
8 . Add 1 ml cold ethanol to recovered supernatant, mix gently, and incubate at 
4° C. for 15 minutes. This is a  good stopping point, if necessary.
9. Centrifuge for 15 minutes at 4 °  C., decant ethanol supernatant, and allow 
pellets to air-dry by inversion on paper towels.
10. Resuspend dried pellets in 400 pi TE (10 mM Tris-HCI, pH 8.0,1 mM EDTA)
11 .Extract resuspended pellet with an equal volume of TE-saturated
phenol (phenol:chloroform:isoamyI alcohol; 50:1:1), centrifuge 2 minutes, 
and carefully remove top phase to a  fresh microtube. Repeat extraction with 
TE-saturated chloroform until chloroform phase (bottom) is clear. One 
extraction is usually sufficient.
12. Add 0.1 volume 3 M sodium acetate (about 40 pi) and fill tubes with cold 
ethanol. Incubate at room temperature 30 minutes to overnight.
13. Centrifuge for 30 minutes to recover precipitated plasmid and dry pellet first 
by inversion on paper towels, then to complete dryness in Savant Speed- 
Vac. W ash dried pellets with 0.5 ml cold 70% ethanol, centrifuge and dry as 
above.
14. Resuspend dried pellet in 40-50 pi TE buffer. 5 pi of this final plasmid 





LS Buffer flow salt)
0.66 ml 1M MgCl2
0.66 ml 1M Tris buffer, pH 7.5 
8.68 ml sterile water
MS Buffenfmedium salt, [ N a d l ^ ^  100 mM)
0.66 ml 1M MgCl2
0.66 ml 1M Tris buffer, pH 7.5 
1.26 ml 5M NaCI 
7.42 ml sterile water
HS Buffer fhioh salt, [NaCilfjna|= 150 mM)
0.66 ml 1M MgCl2
0.66 ml 1M Tris buffer, pH 7.5 
1.89 ml 5 M NaCI
6.79 ml sterile water
KS Buffer (potassium salt, [KCI^jna|= 100 mM)
0.66 ml 1M MgCl2
0.66 ml 1M Tris buffer, pH 7.5 
6.28 ml 1MKCI
2.40 ml sterile water
To m ake active buffer (2X): 20 pi sterile bovine serum  albumin (1 mg/ml, 
[BSA]fjna(= 0.45 pg/ml), 10 pi 1/100 dilution 6-mercaptoethanol (14.26 M 
[BME)jjna|» 32 mM), 14 pi selected restriction buffer ([MgCl2]fina|» 21 mM, 
[ T t e l f j n a r 21 m M )-
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Appendix C
DNA Fragment Preparation and Ligation R eactions
1. Separate restriction fragments on a  0.6% low-melting point agarose (LMP 
agarose, BRL or SeaPlaque agarose, FMC) run at 4° C. with TAE buffer 
(SOX 121 g Tris base, 11.7 g EDTA (acid form) and ~26.5 ml glacial acetic 
acid. Final pH should be 8.2.). Use narrow gel slots; concentrate sam ples by 
ethanol precipitation if necessary.
2. Stain gel with ethidium bromide (for a  10 X 10 cm gel use about 1 pg in 100 
ml cold TAE running buffer). While gel is staining label and tare sufficient 
microtubes to accomodate each fragment to be excised.
3. Bands should be easily visible using a  low-power UV light box. Carefully 
excise fragments of interest from the gel using a  clean razor blade and 
transfer to labeled microtubes. Work quickly to minimize exposure of the 
DNA to damaging UV light. Photograph gels after band excision for a  
record.
4. Determine the weight of the agarose band and add 5 X the weight of TE (i.e. 
a  gel slice weighing 0.1 g will get 500 pi TE). Add 1 pg yeast tRNA a s  a  
carrier (omit if the fragment is to be used a s  a  probe).
5. Heat gel slice at 65° C. for 10 minutes to melt agarose and release the 
fragment.
6 . Cool and extract with an equal volume STE-saturated phenol (no 
chloroform! STE» TE with 0.15 M NaCI). Repeat extraction with 
phenol:chloroform:isoamyI alcohol, then chloroform.
7. Add 0.1 volume 3 M sodium acetate and 2 volumes ethanol. Incubate 
overnight at 4 °  C. for good recovery. Centrifuge for 30 minutes at 4° C to 
recover fragment.
8 . Resuspend fragment in 10 pi TE.
9. Run 2 pi of DNA fragments to be ligated side-by-side on a  microscope slide 
agarose gel. Photograph and visually determine relative concentrations.
10. Mix 1 pi 10X ligation buffer (300 mM Tris, pH 7.6 ,100 mM MgCl2. 50 mM 
dithiothreitol), 1 pi 10 mM ATP, 1 pi T4 DNA ligase (approximately 100 units, 
New England Biolabs) and DNA fragments to be ligated in a  10 pi reaction 
volume. Insert to vector ratios should be between 2:1 and 5:1 for efficient 
ligation. Blunt end ligations should be performed at 4<>-12° C., while 
cohesive end ligations work better at 16° C. Ligations should be allowed to 
react overnight, and should be diluted such that the estimated amount of 
ligated DNA used in transformation with BRL competent cells is ~10 ng.
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Appendix D
Estim ated charge/frlctlonal coefficient ratios for p o ssib le  peptides  
produced by chym otryptic d igestion  of ADR1, ADR1-2C, ADR1-5C
and ADR1-7®
The theoretical mobility (U) of a  macromolecule during zonal electrophoresis 
is a  function of the charge on the macromolecule (ze) and its frictional 
coefficient (f)99:
U= z e / f
Due to numerous complications introduced by interaction of 
macromolecules with solvent ions, endosmosis of the solvent, and distortion of 
the ion field around the macromolecule a s  it moves through the electrophoretic 
medium, there is no simple theoretical treatment which can accurately explain 
the observed mobility of proteins during electrophoresis. The calculations 
performed here are  provided simply as a  reference for comparison to observed 
mobilities of peptides on the 50% pH 3 gel system of West and Bonner68.
To use the formula presented above, the charge (p) and frictional 
coefficients for all the ADR1 and ADR1C chymotryptic peptides capable of being 
phosphorylated were estimated. For estimations of p under the gel conditions 
of pH 3, the following assumptions were made: N-terminal amino groups were 
assum ed to be fully protonated and contributed +1 charge per peptide ; lysine 
and arginine residues were assum ed to be fully protonated and contributed +1 
charge per acidic residue: C-terminal carboxyl groups were assum ed to 
contribute -0.1 charge per residue; and finally, phosphate groups were 
assum ed to contribute -0.86 charge per phosphate incorporated. Due to the 
effect of electrostatic interactions may have on the ionization of charged groups 
(effectively lowering or raising pKa 's), charges were calculated for each peptide 
containing one and two phosphate groups. These two values may be used a s  a 
possible range of variability.
Frictional coefficients were estimated using two different techniques. The 
first simply assum ed that the frictional coefficients of the various peptides were 
directly proportional to the length of the peptide. The second estimate assum ed 
that the frictional coefficients of the peptides is proportional to their molecular 
weight raised to the 2/3 power. The latter estimate is based on empirical 
observations of the mobility of peptides during thin layer electrophoresis100.
Results of these  calculations are presented in Table A.
1 1 6
Table A
Estimated charge/frictlonal coefficient ratios for p o ssib le  peptides
produced by chymotryptic d igestion  of ADR1, ADR1-2C, ADR1-5C
and ADR1-7®
Column A: Sequence of predicted phosphorylated peptides produced by 
chymotryptic digestion of ADR1/, ADR1-20/, ADR1-50/  and ADR1- 
7^/13-galactosidase fusion proteins.
Column B:Calculated molecular weights of the predicted peptides.
Column C:ADR1 residues which the peptides in column A span.
Column D:Number of lysine and arginine residues within the peptide.
Column E:Calculated charge on the peptide at pH 3 with no phosphate groups 
incorporated, p.
Column F: Calculated charge on the peptide at pH 3 with one phosphate 
groups incorporated, p1.
Column G:Calculated charge on the peptide at pH 3 with two phosphate groups 
incorporated, p2.
Column H:Number of residues in the peptide, N.
Column I: Calculated charge on the peptide at pH 3 with one phosphate 
groups incorporated divided by the length of the peptide, p1/N.
Column J: Calculated charge on the peptide at pH 3 with two phosphate groups 
incorporated divided by the length of the peptide, p2/N.
Column K: Calculated charge on the peptide at pH 3 with one phosphate 
groups incorporated divided by the molecular weight of the of 
peptide to the two-thirds power, p1/MWA2/3.
Column L: Calculated charge on the peptide at pH 3 with two phosphate groups 
incorporated divided by the molecular weight of the of peptide to the 
two-thirds power, p2/MWA2/3.
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